Andrew Schally | Academic Influence

Andrew Schally's AcademicInfluence.com Rankings

Andrew Schally

Biology

#251

World Rank

#452

Historical Rank

#146

USA Rank

Endocrinology

#2

World Rank

#2

Historical Rank

#2

USA Rank

biology Degrees

Download Badge

Biology

Andrew Schally's Degrees

PhD Endocrinology McGill University

Why Is Andrew Schally Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Andrzej Viktor "Andrew" Schally is an American endocrinologist of Polish ancestry, who was a corecipient, with Roger Guillemin and Rosalyn Sussman Yalow, of the Nobel Prize in Physiology or Medicine. This award recognized his research in the discovery that the hypothalamus controls hormone production and release by the pituitary gland, which controls the regulation of other hormones in the body. Later in life, Schally utilized his knowledge of hypothalamic hormones to research possible methods for birth control and cancer treatment.

(See a Problem?)

Andrew Schally's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. (1971) (1164)
Gonadotropin-Releasing Hormone: One Polypeptide Regulates Secretion of Luteinizing and Follicle-Stimulating Hormones (1971) (650)
Isolation and properties of the FSH and LH-releasing hormone. (1971) (580)
The regional distribution of somatostatin in the rat brain. (1975) (572)
Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. (1974) (555)
Oncological applications of somatostatin analogues. (1988) (514)
The identity of chemical and hormonal properties of the thyrotropin releasing hormone and pyroglutamyl-histidyl-proline amide. (1969) (490)
Somatostatin: abundance of immunoreactive hormone in rat stomach and pancreas. (1975) (459)
Immunocytochemical localization of corticotropin-releasing factor (CRF) in the rat brain. (1982) (411)
Hypothalamic Regulatory Hormones (1973) (371)
Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. (2001) (360)
Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. (1982) (337)
Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. (1994) (320)
Radioimmunoassay for GH-Release Inhibiting Hormone 1 (1975) (311)
Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. (1989) (299)
Aspects of hypothalamic regulation of the pituitary gland. (1978) (290)
Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. (1995) (289)
Hypothalamic Hormones and Cancer (2001) (288)
Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. (1999) (276)
CNS effects of peripherally administered brain peptides. (1979) (275)
Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly. (1973) (271)
The release of corticotrophin by anterior pituitary tissue in vitro. (1955) (260)
Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients. (1974) (247)
Structure of the porcine LH- and FSH-releasing hormone. II. Confirmation of the proposed structure by conventional sequential analyses. (1971) (247)
Physiological role of somatostatin in the control of growth hormone and thyrotropin secretion. (1976) (242)
The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. (1994) (238)
Transplantation of human islets without immunosuppression (2013) (231)
In vitro bioassay of corticotropin: modification and statistical treatment. (1955) (222)
High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. (1993) (218)
Synthesis of the porcine LH- and FSH-releasing hormone by the solid-phase method. (1971) (214)
Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis☆ (1999) (211)
High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. (1993) (208)
Stimulation of the release of corticotropin from the adenohypophysis by a neurohypophysial factor. (1955) (205)
Isolation and structure of hypothalamic MSH release-inhibiting hormone (1971) (203)
Characteristics and distribution of receptors for [d‐trp6]‐ luteinizing hormone‐releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer (1989) (200)
Free fatty acids block growth hormone (GH) releasing hormone-stimulated GH secretion in man directly at the pituitary. (1987) (199)
Isolation of gamma-amino butyric acid from pig hypothalami and demonstration of its prolactin release-inhibiting (PIF) activity in vivo and in vitro. (1977) (192)
Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer (2008) (191)
Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. (1996) (190)
Androgens Regulate Prostate Cancer Cell Growth via an AMPK-PGC-1α-Mediated Metabolic Switch (2013) (185)
NEW HYPOTHALAMIC HORMONE, CORTICOTROPIN-RELEASING FACTOR, SPECIFICALLY STIMULATES THE RELEASE OF ADRENOCORTICOTROPIC HORMONE AND CORTISOL IN MAN (1982) (184)
Corticotropin-releasing factor stimulates accumulation of adenosine 3', 5'-monophosphate in rat pituitary corticotrophs. (1982) (184)
Mechanisms of Antineoplastic Action of Somatostatin Analogs (1998) (183)
Structure of porcine thyrotropin releasing hormone. (1970) (182)
DOPA potentiation by a hypothalamic factor, MSH release-inhibiting hormone (MIF). (1971) (179)
Stimulation of adenosine 3':5'-cyclic monophosphate accumulation in anterior pituitary gland in vitro by synthetic luteinizing hormone-releasing hormone. (1972) (178)
Chemotherapy targeted to cancers through tumoral hormone receptors (2004) (177)
Inhibition of testicular luteinizing hormone receptor level by treatment with a potent luteinizing hormone-releasing hormone agonist of human chorionic gonadotropin. (1977) (177)
Hypothalamic follicle-stimulating hormone (FSH) and luteinizing hormone (LH)-regulating hormone: structure, physiology, and clinical studies. (1971) (174)
Production of antiserum to LH-releasing hormone (LH-RH) associated with gonadal atrophy in rabbits: development of radioimmunoassays for LH-RH. (1973) (174)
Blockade of the stress-induced decrease in blood GH by anti-somatostatin serum in rats. (1976) (170)
Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. (2000) (170)
Immunocytochemical localization of growth hormone-releasing factor in the rat hypothalamus. (1984) (168)
Effect of monosodium glutamate on some endocrine functions. (1971) (168)
Synthetic thyrotropin-releasing hormone. A potent stimulator of thyrotropin secretion in man. (1971) (168)
Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist (2012) (165)
High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. (2000) (165)
Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. (1985) (165)
Presence of receptors for bombesin/gastrin‐releasing peptide and mRNA for three receptor subtypes in human prostate cancers (2000) (165)
Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. (1998) (164)
DIRECT INHIBITION OF GASTRIC ACID AND PEPSIN SECRETION BY GROWTH-HORMONE RELEASE-INHIBITING HORMONE IN CATS (1975) (163)
Hypothalamic regulatory hormones. (1973) (163)
Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. (1986) (159)
Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone (2007) (158)
Isolation and structure of pro-somatostatin: a putative somatostatin precursor from pig hypothalamus. (1980) (158)
Characterization of high‐affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC‐3 and DU‐145: Internalization of receptor bound 125I‐(Tyr4) bombesin by tumor cells (1994) (157)
Stimulation of cyclic AMP accumulation and corticotropin release by synthetic ovine corticotropin-releasing factor in rat anterior pituitary cells: site of glucocorticoid action. (1982) (155)
Radioimmunoassay of somatostatin. (1978) (155)
Suppression of prolactin release by a purified porcine PIF preparation and catecholamines infused into a rat hypophysial portal vessel. (1974) (151)
RANDOMISED CONTROLLED STUDY OF ORCHIDECTOMY VS LONG-ACTING D-TRP-6-LHRH MICROCAPSULES IN ADVANCED PROSTATIC CARCINOMA (1985) (149)
CORTICOTROPHIN RELEASING FACTOR: RESPONSES IN NORMAL SUBJECTS AND PATIENTS WITH DISORDERS OF THE HYPOTHALAMUS AND PITUITARY (1984) (148)
Immunohistological study of the origin of LH-RH-containing nerve fibers of the rat hypothalamus (1976) (147)
Isolation and properties of porcine thyrotropin-releasing hormone. (1969) (147)
Potent inhibitory activity of [D-Leu6, Des-Gly-NH2(10)]LHRH ethylamide on LH/hCG and PRL testicular receptor levels in the rat. (1977) (146)
LH-RH-containing neural elements in the rat hypothalamus. (1975) (146)
Growth Hormone Release Inhibiting Hormone in Acromegaly (1974) (145)
Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. (1997) (145)
The LHRH antagonist cetrorelix: a review. (2000) (145)
Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. (1998) (144)
Isolation and structure of somatostatin from porcine hypothalami. (1976) (144)
Hypothalamic neurohormones regulating anterior pituitary function. (1968) (144)
Effect of intraventricular injection of dopamine, noreprinephrine, acetylcholine, and 5-hydroxytryptamine on immunoreactive somatostatin release into rat hypophyseal portal blood. (1979) (141)
Electron microscopic immunohistochemical localization of growth hormone-release inhibiting hormone (somatostatin) in the rat median eminence. (1974) (140)
Inhibition of adenosine 3',5'-monophosphate accumulation in anterior pituitary gland in vitro by growth hormone-release inhibiting hormone. (1974) (140)
Responses to thyrotropin-releasing hormone in patients with renal failure and after infusion in normal men. (1973) (139)
Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis (2002) (137)
The paraventriculo-infundibular corticotropin releasing factor (CRF) pathway as revealed by immunocytochemistry in long-term hypophysectomized or adrenalectomized rats (1983) (137)
Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. (1981) (135)
sst2 Somatostatin Receptor Mediates Cell Cycle Arrest and Induction of p27 Kip1 (1999) (135)
Antagonistic Analogs of Growth Hormone-releasing Hormone: New Potential Antitumor Agents (1999) (135)
Isolation of the luteinizing hormone and follicle-stimulating hormone-releasing hormone from porcine hypothalami. (1971) (133)
Studies on the interaction of endorphins, substance P. and endogenous somatostatin in growth hormone and prolactin release in rats. (1978) (132)
Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. (1995) (132)
Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa‐2 cell line (1985) (131)
Luteinizing hormone-releasing hormone (LH-RH) content of the hypothalamic nuclei in rat. (1974) (130)
Discovery of modification of the synthetic tripeptide-sequence of the thyrotropin releasing hormone having activity. (1969) (128)
Synthesis and opioid activities of stereoisomers and other D-amino acid analogs of methionine-enkephalin. (1976) (125)
Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules. (1984) (125)
Antitumor Effects of Analogs of Hypothalamic Hormones in Endocrine-Dependent Cancers (1984) (125)
Enkephalin and a potent analog facilitate maze performance after intraperitoneal administration in rats (1976) (123)
Glucagon control of fasting glucose in man. (1974) (123)
Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines. (1992) (121)
Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. (2000) (121)
Neuroendocrine influence on attention and memory. (1972) (121)
Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. (1995) (121)
MIF-I's differential actions as an opiate antagonist (1979) (120)
Affective state and thyrotropin and prolactin responses after repeated injections of thyrotropin-releasing hormone in depressed patients. (1974) (120)
Growth-Inhibitory Actions of Analogues of Luteinizing Hormone Releasing Hormone on Tumor Cells (1997) (118)
New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues. (2009) (118)
Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance (2014) (118)
Effect of sex steroids on pituitary responses to LH-and FSH-releasing hormone in vitro. (1973) (118)
Evaluation of receptors for somatostatin in various tumors using different analogs. (1990) (118)
Peptide analogs in the therapy of prostate cancer (2000) (117)
New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. (2003) (116)
Receptors for luteinizing hormone‐releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia (1989) (115)
Edward T. Tyler Prize Oration: LH-releasing hormone and its analogues: recent basic and clinical investigations. (1976) (115)
Increase in basal and thyrotropin-releasing hormone (TRH)-stimulated secretion of thyrotropin (TSH) by passive immunization with antiserum to somatostatin in rats. (1976) (115)
Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by D-amino acid substitutions in position 6. (1976) (111)
Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. (1990) (108)
Psycho-physiologic correlates of MSH activity in man. (1971) (108)
Isolation of thyrotropin releasing factor (TRF) from porcine hypothalamus. (1966) (106)
The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. (2005) (106)
Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. (1997) (106)
Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers. (1999) (105)
The half-life, metabolism and excretion of tritiated luteinizing hormone-releasing hormone (LH-RH) in man. (1973) (104)
Release of LH and FSH after administration of synthetic LH-releasing hormone. (1972) (104)
Immunohistochemical localization of luteinizing hormone-releasing hormone in the rat median eminence. (1974) (103)
Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma. (1999) (103)
Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095). (1991) (103)
Immunoreactive somatostatin in rat hypophyseal portal blood: effects of anesthetics. (1979) (103)
Distribution of 3H-α-MSH in rat brain (1976) (102)
Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro. (1994) (101)
Localization of growth hormone-release-inhibiting hormone (somatostatin) in the rat brain. (1975) (101)
Neuropharmacological actions of enkephalin after systemic administration. (1976) (100)
Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors. (1991) (100)
Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. (1987) (99)
cKit+ cardiac progenitors of neural crest origin (2015) (98)
Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin. (1990) (98)
Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin. (1989) (98)
Enkephalin and other peptides reduce passiveness (1978) (97)
Membrane Receptors for Peptides in Experimental and Human Pancreatic Cancers (1989) (97)
Proceedings: Effect of somatostatin on motilin levels and gastric emptying. (1975) (96)
Porcine thyrotropin releasing hormone is (pyro)glu-his-pro(NH2). (1970) (95)
Gonadotropin and alpha-subunit secretion during long term pituitary suppression by D-Trp6-luteinizing hormone-releasing hormone microcapsules as treatment of precocious puberty. (1987) (95)
Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. 1991. (2002) (94)
Corticotropin-releasing factor (CRF)-like immunoreactivity in the vertebrate endocrine pancreas. (1983) (94)
Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction (2010) (93)
Blood-brain barrier, half-time disappearance, and brain distribution for labeled enkephalin and a potent analog (1976) (92)
Stimulation of release and synthesis of luteinizing hormone(LH) and follicle stimulating hormone(FSH) in tissue culture of rat pituitaries in response to natural and synthetic LH and FSH releasing hormone. (1972) (92)
Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. (1994) (91)
The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers (2000) (91)
Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors. (1998) (91)
Inhibition of growth of PC‐82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC‐3095 or combination of agonist [D‐Trp6]‐luteinizing hormone‐releasing hormone and somatostatin analog RC‐160 (1992) (91)
Behavioral inhibition as modified by melanocyte-stimulating hormone (MSH) and light-dark conditions. (1971) (91)
Responses to the antagonistic analog of LH‐RH (SB‐75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer (1994) (90)
Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. (1997) (90)
Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats. (1990) (90)
Synthesis and biological properties of (D-Ala-6, des-Gly-NH2-10)-LH-RH ethylamide, a peptide with greatly enhanced LH- and FSH- releasing activity. (1974) (90)
S-nitrosoglutathione reductase (GSNOR) enhances vasculogenesis by mesenchymal stem cells (2013) (90)
Letter: Immunohistochemical localization of somatostatin in the rat pancreas. (1975) (89)
High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin. (1996) (89)
Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone. (1995) (89)
Abnormalities in the release of TSH in response to thyrotropin-releasing hormone (TRH) in patients with disorders of the pituitary, hypothalamus and basal ganglia. (1972) (89)
Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone. (2000) (88)
On the Presence in Hog Hypothalamus of (β-Corticotropin Releasing Factor, α- and (β-Melanocyte Stimulating Hormones, Adrenocorticotropin, Lysine-Vasopressin and Oxytocin (1962) (87)
Potent prolactin and growth hormone releasing activity of more analogues of Met-enkephalin (1977) (87)
Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. (1997) (87)
Minireview. Targeting of Cytotoxic Luteinizing Hormone-Releasing Hormone Analogs to Breast, Ovarian, Endometrial, and Prostate Cancers1 (2005) (86)
AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors (2012) (85)
Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix. (1996) (85)
Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. (1999) (85)
Augmentation of Pituitary Responsiveness to LH-Releasing Hormone (LH-RH) by Estrogen 1 (1971) (85)
Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. (1989) (85)
Changes in pituitary responsiveness to luteinizing hormone-releasing hormone (LH-RH) in anestrous ewes pretreated with estradiol benzoate. (1971) (84)
Comparison of methionine-enkephalin and morphine in the stimulation of gastric acid secretion in the dog. (1980) (84)
Pituitary responsiveness to purified luteinizing hormone-releasing hormone (LH-RH) at various stages of the estrous cycle in sheep. (1971) (84)
Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. (1997) (84)
Additional evidence that small amounts of a peptide can cross the blood-brain barrier (1979) (83)
Blockade of the preovulatory surge of LH and FSH and of ovulation by anti-LH-RH serum in rats. (1974) (83)
Growth hormone-releasing hormone: not only a neurohormone (2011) (83)
Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. (1994) (83)
Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. (1999) (82)
Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone. (1994) (82)
Biphasic effect of estradiol benzoate on the pituitary responsiveness to LH-RH. (1974) (81)
Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies. (2000) (81)
Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. (2000) (81)
Extrapigmentary effects of melanocyte-stimulating hormone in amenorrhoeic women. (1968) (81)
A chemically labeled cytotoxic agent: two-photon fluorophore for optical tracking of cellular pathway in chemotherapy. (1999) (81)
Recent approaches to fertility control based on derivative of LH-RH. (1980) (81)
Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects. (1988) (80)
Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N-terminal D-Trp or D-Tpi. (2009) (80)
The amino acid sequence of a peptide with growth hormone-releasing activity isolated from porcine hypothalamus. (1971) (80)
MSH activity in plasma and pituitaries of rats after various treatments. (1969) (80)
High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. (2000) (79)
Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. (1997) (79)
New approaches to the therapy of various tumors based on peptide analogues. (2008) (79)
Effect of somatostatin analog RC‐160 and bombesin/gastrin releasing peptide antagonist RC‐3095 on growth of PC‐3 human prostate‐cancer xenografts in nude mice (1993) (79)
Corticotropin releasing factor (CRF): origin and course of afferent pathways to the median eminence (ME) of the rat hypothalamus. (1984) (79)
Solid phase synthesis of growth hormone-release inhibiting factor. (1973) (79)
Synthesis and biological actions of prosomatostatin. (1980) (79)
Behavioral and electrographic changes in rat and man after MSH. (1975) (78)
Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. (1999) (77)
Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia (2011) (77)
Effect of somatostatin on the proliferation of mouse spleen lymphocytes in vitro. (1985) (77)
Synthesis and biological properties of (Leu-6)-LH-RH and (D-Leu-6,desGly-NH210)-LH-RH ethylamide. (1974) (77)
LH‐RH Agonists and Antagonists (1980) (77)
Effect of corticotropin-releasing factor, dexamethasone and actinomycin D on the release of ACTH from rat pituitaries in vivo and in vitro. (1969) (76)
Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy. (2005) (76)
LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia (2011) (76)
Enterogastrone Inhibits Eating by Fasted Mice (1967) (76)
The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas (2002) (75)
Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. (2002) (75)
Inhibition of growth of MKN45 human gastric‐carcinoma xenografts in nude mice by treatment with bombesin/gastrin‐releasing‐peptide antagonist (RC‐3095) and somatostatin analogue RC‐160 (1994) (75)
Atropine blockade of growth hormone (GH)-releasing hormone-induced GH secretion in man is not exerted at pituitary level. (1986) (74)
Interactions of L-thyroxine or L-triiodothyronine and thyrotropin-releasing factor on the release and synthesis of thyrotropin from the anterior pituitary gland of mice. (1967) (74)
Growth hormone-releasing hormone: Extrapituitary effects in physiology and pathology (2010) (74)
Favorable outcome of experimental islet xenotransplantation without immunosuppression in a nonhuman primate model of diabetes (2017) (74)
Stimulation of LH release in men and women by LH-releasing hormone purified from porcine hypothalami. (1969) (74)
Reduction of testicular luteinizing hormone/human chorionic gonadotropin receptors by [D-Trp6]-luteinizing hormone releasing hormone in hypophysectomized rats. (1979) (73)
Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. (1997) (73)
LH-RH analogues: I. Their impact on reproductive medicine. (1999) (73)
Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer. (2002) (73)
Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers (2003) (73)
Serum LH levels in bulls treated with synthetic luteinizing hormone-releasing hormone-follicle stimulating hormone-releasing hormone (LH-RH-FSH-RH). (1973) (72)
Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis (2019) (72)
Assays for corticotropin-releasing factor (CRF) using rats treated with morphine, chlorpromazine, dexamethasone and Nembutal. (1967) (72)
On the half life of thyrotropin-releasing hormone in rats. (1972) (72)
GH-RIH-containing neural elements in the rat hypothalamus (1975) (72)
Oxotremorine Antagonism by a Hypothalamic Hormone, Melanocyte-Stimulating Hormone Release-Inhibiting Factor (MIF) (1972) (71)
Hypothalamo-pituitary and immune-dependent adrenal regulation during systemic inflammation (2013) (71)
Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs (2002) (71)
Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers (2000) (71)
The effect of hypothalamic deafferentation on somatostatin-like activity in the rat brain. (1977) (70)
New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs (2004) (70)
Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats. (1996) (69)
Studies on the mechanism of growth hormone and thyrotropin responses to somatostatin antiserum in anesthetized rats. (1978) (68)
Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters. (1991) (68)
Immunoreactive LH-releasing hormone in plasma: midcycle elevation in women. (1974) (68)
Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone. (1995) (68)
Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors. (2011) (68)
Deserpidine antagonism by a tripeptide, L-prolyl-L-leucyglycinamide. (1973) (68)
The Binding of Bombesin and Somatostatin and Their Analogs to Human Colon Cancers (1992) (67)
Long-term Infusion of Growth Hormone Release Inhibiting Hormone in Acromegaly: Effects on Pituitary and Pancreatic Hormones (1974) (67)
Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone (2001) (67)
Electroencephalographic measures of melanocyte-stimulating hormone activity. (1971) (67)
Stimulation of FSH and LH release in vitro by natural and synthetic LH and FSH releasing hormone. (1972) (67)
Reversal of Somatostatin Inhibition of Insulin and Glucagon Secretion (1976) (66)
Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. (1992) (66)
Potentiation of the inhibitory effect of growth hormone‐releasing hormone antagonists on PC‐3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways (2000) (66)
Behavioral aspects of melanocyte-stimulating hormone (MSH). (1973) (65)
Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone. (1999) (65)
Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. (1998) (65)
Luteinizing hormone-releasing hormone agonist triptorelin antagonizes signal transduction and mitogenic activity of epidermal growth factor in human ovarian and endometrial cancer cell lines. (1996) (65)
Ovulation confirmed by pregnancy after infusion of porcine LH-RH. (1971) (65)
Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines (2008) (65)
Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases (2012) (64)
Hypothalamic and Other Peptide Hormones (2003) (64)
Luteinizing hormone‐releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma: A prospective double blind randomized trial (1996) (64)
Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75. (1990) (64)
Studies on the pituitary responsiveness to luteinizing hormone-releasing hormone (LH-RH) in intact male rats of different ages. (1972) (64)
Distribution, half-life, and excretion of 14 C- and 3 H-labeled L-prolyl-L-leucyl-glycinamide in the rat. (1973) (64)
Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers. (2000) (63)
Peptide antagonists of LH-RH: large increases in antiovulatory activities produced by basic D-amino acids in the six position. (1982) (63)
A study on the interaction of the thyrotropin-releasing factor and L-triiodothyronine: effects of puromycin and cycloheximide. (1968) (63)
Comparison of different agonists and antagonists of luteinizing hormone-releasing hormone for receptor-binding ability to rat pituitary and human breast cancer membranes. (1989) (63)
Agonist of growth hormone-releasing hormone as a potential effector for survival and proliferation of pancreatic islets (2010) (63)
Luteinizing hormone‐releasing hormone antagonist Cetrorelix (SB‐75) and bombesin antagonist RC‐3940‐II inhibit the growth of androgen‐independent PC‐3 prostate cancer in nude mice (1997) (63)
Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells. (1992) (63)
FSH-releasing hormone and LH-releasing hormone. (1972) (63)
The Expression of Growth Hormone-Releasing Hormone (GHRH) and its Receptor Splice Variants in Human Breast Cancer Lines; The Evaluation of Signaling Mechanisms in the Stimulation of Cell Proliferation (2004) (63)
Effect of gonadal steroids on the response to LH-RH in intact and castrated male rats. (1974) (63)
The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. (2017) (62)
Inhibitory effects of analogs of luteinizing hormone‐releasing hormone and somatostatin on pancreatic cancers in hamsters events that accompany tumor regression (1990) (62)
Neuroendocrine responses to physical and psychological stress. (1973) (62)
Studies on the Inactivation of Thyrotropin-Releasing Hormone (TRH)∗ (1969) (62)
P53, GHRH, inflammation and cancer (2018) (62)
Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors. (1993) (61)
Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. (1995) (61)
Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo. (1994) (61)
Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor (2003) (61)
Targeting gastrin releasing peptide receptors: New options for the therapy and diagnosis of cancer. (2010) (61)
Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line (2008) (61)
The hypothalamus and reproduction. (1972) (61)
Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice (2000) (61)
Absence of LH-RH binding sites in corpora lutea from rhesus monkeys (Macacca mulatta). (1981) (60)
Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095. (1992) (60)
LH-releasing activity of potent LH-RH analogs in vitro. (1975) (60)
in vivo inhibition of PC‐3 human androgen‐independent prostate cancer by a targeted cytotoxic bombesin analogue, AN‐215 (2000) (60)
Antagonists of growth hormone-releasing hormone in oncology. (2006) (59)
Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095. (1998) (59)
MSH activity in pituitaries of rats treated with hypothalamic extracts. (1966) (58)
General activity in intact and hypophysectomized rats after administration of melanocyte-stimulating hormone (MSH), melatonin, and PRO-LEU-GLY-NH 2 . (1973) (58)
Inhibition of growth of human small cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH). (1996) (58)
Inhibition of prostate tumors by agonistic and antagonistic analogs of LH‐RH (1983) (58)
Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone. (1987) (58)
Antagonists of growth hormone-releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice. (2000) (58)
Site of inactivation of thyrotropin-releasing hormone by human plasma. (1971) (58)
Autoregulation of Release of Melanocyte Stimulating Hormone from the Rat Pituitary (1967) (57)
Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI) (2011) (57)
Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses. (1998) (57)
Progesterone blockade of the ovulatory response to intrapituitary infusion of LH-RH in rabbits. (1971) (57)
A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice. (2001) (57)
Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. (1994) (57)
Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours. (2000) (57)
Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. (2007) (57)
Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms. (1984) (57)
Hypothalamic hormones: from neuroendocrinology to cancer therapy. (1994) (57)
A corticotrophin-releasing factor: partial purification and amino acid composition. (1958) (56)
Somatostatin, Its Receptors and Analogs, in Lung Cancer (2001) (56)
Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75. (1990) (56)
Effect of somatostatin on myoelectrical activity of small bowel. (1978) (56)
Protective effects of analogs of luteinizing hormone-releasing hormone against x-radiation-induced testicular damage in rats. (1987) (56)
Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095. (1997) (56)
Radioimmunoassay of DSIP-like material in rat brain (1978) (56)
Growth hormone release inhibiting hormone: actions on thyrotrophin and prolactin secretion after thyrotrophinreleasing hormone. (1975) (55)
Transplantation of bovine adrenocortical cells encapsulated in alginate (2015) (55)
Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice. (1993) (55)
Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities (2014) (55)
Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions (2001) (54)
Growth hormone release inhibiting hormone: neuropharmacological studies. (1974) (54)
Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice. (2001) (54)
Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. (2010) (54)
Phospholipides and the secretion of adrenocorticotropin and of corticosteroids. (1958) (54)
Inhibition of growth hormone and thyrotropin release by growth hormone-release inhibiting hormone. (1974) (54)
Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone. (1997) (54)
A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers. (1997) (54)
Isolation and structure of pro-methionine-enkephalin: Potential enkephalin precursor from porcine hypothalamus. (1979) (53)
Evidence for peptide nature of LH and FSH-releasing hormones. (1971) (53)
Regulation of luteinizing hormone-releasing hormone receptor binding by heterologous and autologous receptor-stimulated tyrosine phosphorylation. (1991) (53)
Corticotropin-releasing factor (CRF)-like immunoreactivity in the gastro-entero-pancreatic endocrine system (1984) (53)
PURIFICATION OF LUTEINIZING HORMONE-RELEASING FACTOR FROM BOVINE HYPOTHALAMUS. (1964) (53)
GRHきっ坑薬のMZ‐5‐156は,ヌードマウスのDU‐145ヒトアンドロゲン非依存性前立腺癌の成長を阻害し,腫よう内のIGF2のレベル及びmRNA発現を低下させる (1998) (53)
Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide (1999) (53)
Inhibition of pancreatic secretion by enkephalin and morphine in dogs (1978) (53)
Treatment of leiomyomata uteri with D-Trp6-luteinizing hormone-releasing hormone (1987) (52)
Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone. (1989) (52)
Pituitary-adrenal activation in rats with hereditary hypothalamic diabetes insipidus. (1967) (52)
Agonist of growth hormone-releasing hormone reduces pneumolysin-induced pulmonary permeability edema (2012) (52)
Therapy of advanced ovarian cancer with D-Trp-6-LH-RH (decapeptyl) microcapsules. (1988) (52)
Luteinizing hormone-releasing hormone (LH-RH) activity of some synthetic polypeptides. I. Fragments shorter than decapeptide. (1972) (52)
D-TRP6-ANALOGUE OF LUTEINISING HORMONE RELEASING HORMONE IN COMBINATION WITH CYPROTERONE ACETATE TO TREAT PRECOCIOUS PUBERTY (1974) (52)
Stimulation of release of LH by synthetic LH-RF in vivo. I. A comparative study of natural and synthetic hormones. (1972) (52)
Bombesin/gastrin‐releasing peptide antagonists RC‐3095 and RC‐3940‐II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H‐69 small cell lung carcinoma (1998) (52)
Extrapituitary effects of the growth hormone-releasing hormone. (2005) (52)
Inhibition of growth of the transplantable rat chondrosarcoma by analogs of hypothalamic hormones. (1983) (51)
Depolarization- and ionophore-induced release of octacosa somatostatin from stalk median eminence synaptosomes. (1981) (51)
The distribution, half-life, and excretion of tritiated luteinizing hormone-releasing hormone (LH-RH) in rats. (1973) (51)
Radiolabeled somatostatin analogs in prostate cancer. (1997) (51)
Evidence for the Existence of Two Corticotrophin-releasing Factors, α and β (1960) (51)
D-Tryptophan-6 analog of luteinizing hormone-releasing hormone as a protective agent against testicular damage caused by cyclophosphamide in baboons. (1985) (51)
Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK‐ES‐1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone‐releasing hormone (2002) (51)
Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1–STAT3/NF-κB signaling (2016) (51)
Inhibition of pituitary-testicular function with [D-Trp6] luteinizing hormone-releasing hormone in rhesus monkeys. (1982) (51)
Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs (1999) (51)
Successful Induction of Ovulation with Synthetic Luteinizing Hormone-Releasing Hormone in Anovulatory Infertility (1972) (51)
IN VITRO AND IN VIVO STIMULATION OF THE RELEASE OF LUTEINIZING HORMONE. (1964) (50)
Effects of synthetic luteinizing hormone-releasing hormone-follicle stimulating hormone-releasing hormone (LH-RH-FSH-RH) on serum LH, serum FSH and ovulation in anestrous ewes. (1972) (50)
Stimulatory and inhibitory analogs of luteinizing hormone releasing hormone. (1974) (50)
Targeted cytotoxic analogue of bombesin/ gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice (1999) (50)
Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor (2007) (50)
Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice. (1994) (50)
Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes (2002) (50)
Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma. (2003) (50)
Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238. (2000) (50)
Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH-releasing hormone antagonist Cetrorelix. (2002) (49)
Stimulation of FSH release in vivo by prolonged infusion of synthetic LH-RH. (1972) (49)
Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system. (2004) (49)
Clinical experience with hypothalamic releasing hormones. 2. Luteinizing hormone-releasing hormone and other hypophysiotropic releasing hormones. (1972) (49)
Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers (2004) (49)
Functional relationship between the pars intermedia and ACTH secretion in the rat. (1970) (49)
Acceleration of wound healing by growth hormone-releasing hormone and its agonists (2010) (48)
Pituitary and serum FSH and LH levels after massive and selective depletion of the germinal epithelium in the rat testis. (1973) (48)
Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists or agonists. (1990) (48)
Corticotropin releasing factor (CRF): immunocytochemical localization and radioimmunoassay (RIA). (1982) (48)
Chromatography and hormonal activities of dog hypothalamus. (1962) (48)
Response to D-Trp-6-luteinising hormone releasing hormone (Decapeptyl) microcapsules in advanced ovarian cancer (1988) (48)
Somatostatin analogs which inhibit glucagon and growth hormone more than insulin release. (1977) (48)
Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice. (1998) (48)
The Effect of Surgical Isolation of the Hypothalamus on Its Luteinizing Hormone-Releasing Hormone Content (1976) (48)
Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status. (2002) (48)
Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice. (2005) (48)
Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. (2003) (48)
Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125 (2014) (47)
Modulation of pancreatic islets-stress axis by hypothalamic releasing hormones and 11β-hydroxysteroid dehydrogenase (2011) (47)
Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers (2002) (47)
Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix down-regulates the mRNA expression of pituitary receptors for LH-RH by counteracting the stimulatory effect of endogenous LH-RH. (2001) (47)
Effects of high-fat diet on the patterns of prostatic cancer induced in rats by N-nitrosobis(2-oxopropyl)amine and testosterone. (1991) (47)
The presence of LHRH‐like receptors in Dunning R3327H prostate tumors (1983) (47)
Blockade of release of growth hormone by brain norepinephrine depletors. (1967) (47)
The effects of MSH on a restricted passive avoidance response (1972) (47)
Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers. (1999) (47)
Growth hormone-releasing hormone as an agonist of the ghrelin receptor GHS-R1a (2008) (47)
Pituitary responsiveness to LH-releasing hormone in intact female rats of different ages. (1972) (47)
Highly potent analogues of luteinizing hormone-releasing hormone containing D-phenylalanine nitrogen mustard in position 6. (1989) (46)
Administration of LH-releasing hormone to selected subjects. (1970) (46)
Regulation of endometrial cancer cell growth by insulin-like growth factors and the luteinizing hormone-releasing hormone antagonist SB-75 (1993) (46)
TREATMENT OF PRECOCIOUS PUBERTY WITH LHRH ANALOGUE IN COMBINATION WITH CYPROTERONE ACETATE—FURTHER EXPERIENCE (1984) (46)
Inhibition of growth of MX‐1, MCF‐7‐MIII and MDA‐MB‐231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN‐238 (1999) (46)
Antitumor effects of analogs of LH-RH and somatostatin: Experimental and clinical studies (1990) (46)
Presence and characteristics of receptors for [D-Trp6]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer. (1998) (46)
GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells (2009) (45)
Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells (2009) (45)
Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: Antiproliferative effects of peptide analogues (2009) (45)
Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. (2003) (45)
Interaction between hypothalamic peptides in a superfused pituitary cell system (1984) (45)
SUPPRESSION OF GONADOTROPHIN RELEASE IN MAN BY AN INHIBITORY ANALOGUE OF L.H.-RELEASING HORMONE (1977) (45)
Unusual anti-reproductive properties of the analog [d-Leu6,des-Gly-NH2(10)]-luteinizing hormone-releasing hormone ethylamide in male rats. (1978) (45)
Peripheral administration of hypothalamic peptides results in CNS changes. (1978) (45)
Use of synthetic luteinizing hormone-releasing hormone in treatment of oligospermic men: a preliminary report. (1975) (45)
Investigation of the combination of the agonist D‐Trp‐6‐LH‐RH and the antiandrogen flutamide in the treatment of dunning R‐3327H prostate cancer model (1985) (45)
Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives. (2014) (45)
Effect of combination treatment with analogs of luteinizing hormone‐releasing hormone (LH‐RH) or somatostatin and 5‐fluorouracil on pancreatic cancer in hamsters (1991) (45)
Expression of mRNA for growth hormone-releasing hormone and splice variants of GHRH receptors in human malignant bone tumors (2002) (45)
Effects of a growth hormone-releasing hormone antagonist on telomerase activity, oxidative stress, longevity, and aging in mice (2010) (45)
CNS effects of somatostatin. (1978) (45)
Purification of a bovine hypothalamic factor which elevates pituitary MSH levels in rats. (1966) (44)
Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers. (2001) (44)
Luteinizing Hormone-Releasing Hormone Receptor-Targeted Chemotherapy Using AN-152 (2009) (44)
Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207. (2000) (44)
MSH Activity in Rat Pituitaries After Pinealectomy.∗ † (1967) (44)
Suppression of androgen production by D-tryptophan-6-luteinizing hormone-releasing hormone in man. (1981) (44)
Effect of luteinizing hormone-releasing hormone analogs on the rat ovarian follicle development. (1997) (44)
Potent bombesin antagonists with C-terminal Leu-psi(CH2-N)-Tac-NH2 or its derivatives. (1994) (43)
Progesterone supression of LH-releasing hormone-induced stimulation of LH release in rats. (1970) (43)
Inhibitory effects of analogs of luteinizing hormone‐releasing hormone on the growth of the androgen‐independent dunning R‐3327‐AT‐1 rat prostate cancer (1994) (43)
Clinical experience with hypothalamic releasing hormones. 1. Thyrotropin-releasing hormone. (1972) (43)
Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer (2009) (43)
Radioimmunoassay for 6-D-tryptophan analog of luteinizing hormone-releasing hormone: measurement of serum levels after administration of long-acting microcapsule formulations. (1985) (43)
Purification of a catecholamine-rich fraction with prolactin release-inhibiting factor (PIF) activity from porcine hypothalami. (1976) (43)
Highly active position eight analogues of somatostatin and separation of peptide diastereomers by partition chromatography. (1978) (43)
Synthetic LH-releasing hormone (LH-RH) administered to normal men by different routes. (1973) (43)
Expression of Receptors for Luteinizing Hormone-Releasing Hormone (LH-RH) in Prostate Cancers following Therapy with LH-RH Agonists (2010) (43)
Comparison of Somatostatin and Its Highly Potent Hexa- and Octapeptide Analogs on Exocrine and Endocrine Pancreatic Secretion (1988) (43)
The status of the corticotropin releasing factor (CRF). (1977) (43)
Studies on retarded growth of rats with hereditary hypothalamic diabetes insipidus. (1968) (43)
Effect of catecholamines on the TRH-stimulated release of prolactin and growth hormone from sheep pituitaries in vitro. (1974) (43)
Plasma gonadotropins after administration of LH-releasing hormone in patients with renal or hepatic failure. (1975) (43)
IMPAIRMENT OF PLATELET FUNCTION BY GROWTH-HORMONE RELEASE- INHIBITING HORMONE (1975) (43)
Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC‐3 and DU‐145 human androgen‐independent prostate cancers (2005) (43)
Antitumor effects of somatostatin mediated by the stimulation of tyrosine phosphatase. (1990) (43)
Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin (2003) (42)
Inhibitory effect of bombesin/gastrin‐releasing peptide antagonist RC‐3095 and luteinizing hormone—releasing hormone antagonist SB‐75 on the growth of MCF‐7 MIII human breast cancer xenografts in athymic nude mice (1994) (42)
Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling. (2005) (42)
DSIP — more than a sleep peptide? (1980) (42)
Effect of active and passive immunization with luteinizing hormone-releasing hormone on serum luteinizing hormone and follicle-stimulating hormone levels and the ultrastructure of the pituitary gonadotrophs in castrated male rats. (1976) (42)
Antagonists of bombesin/gastrin‐releasing peptide inhibit growth of SW‐1990 human pancreatic adenocarcinoma and production of cyclic AMP (1995) (42)
Treatment of N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules. (1989) (42)
Prolactin and luteinizing hormone‐releasing hormone receptors in human benign prostatic hyperplasia and prostate cancer (1988) (42)
Synergistic effects of bombesin and epidermal growth factor on cancers. (1994) (42)
Luteinizing hormone–releasing hormone (LH–RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors (1998) (42)
Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10. (2004) (42)
Effects of long-term treatment with the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the levels of pituitary LHRH receptors and their mRNA expression in rats (2002) (42)
Enhancement of immunoreactive somatostatin release into hypophysial portal blood by electrical stimulation of the preoptic area in the rat. (1979) (42)
Parallel stimulation of cyclic AMP accumulation and LH and FSH release by analogs of LH-RH in vitro (1974) (41)
Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin. (1988) (41)
Dissociation of effects of LH-RH analogs on pituitary regulation and reproductive behavior (1980) (41)
Hypoglycemia, stress and growth hormone release: blockade of growth hormone release by drugs acting on the central nervous system. (1967) (41)
Pituitary hormonal reserve in patients presenting hyperprolactinemia, intrasellar masses, and amenorrhea without galactorrhea. (1975) (41)
Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers (2012) (41)
Acute promyelocytic leukemia (APL): a review of the literature (2020) (41)
An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer (2013) (41)
Isolation and amino acid sequence of alpha2-corticotropin-releasing factor (alpha2-CRF) from hog pituitary glands. (1962) (41)
Somatostatin analogue rc‐160 inhibits the growth of transplanted colon cancer in rats (1991) (41)
Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth. (2001) (41)
Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor. (2000) (41)
Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer (2014) (41)
Actions and Potential Therapeutic Applications of Growth Hormone-Releasing Hormone Agonists. (2019) (40)
RESPONSE TO D-TRP-6-LH-RH IN ADVANCED ADENOCARCINOMA OF PANCREAS (1986) (40)
Unusual Anti-Reproductive Properties of the Analog [d-Leu6,Des-Gly- N H 2 10 ]-Luteinizing Hormone-Releasing Hormone Ethylamide in Male Rats**Supported in part by National Institutes of Health Grant 5 P50 HD08338. (1978) (40)
Somatostatin receptor expression in lung cancer. (1994) (40)
Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. (1992) (40)
Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238. (2000) (40)
Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas (2003) (40)
Somatostatin Analogue RC‐160 and LH‐RH Antagonist SB‐75 Inhibit Growth of MIA PaCa‐2 Human Pancreatic Cancer Xenografts in Nude Mice (1993) (40)
Distribution of radioactivity in the organs of the rat and mouse after injection of (125I)alpha-melanocyte-stimulating hormone. (1975) (40)
Effectf of synthetic luteinizing hormone-releasing hormone (LH-RH) in two brothers with hypogonadotropic hypogonadism and anosmia. (1973) (40)
Radioautographic localization of radioactivity in rat brain after intracarotid injection of 125I-α-melanocyte-stimulating hormone (1975) (40)
Synthesis and In Vitro Evaluation of New Potent Antagonists of Growth Hormone-Releasing Hormone (GH-RH) (1997) (40)
GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro. (2010) (40)
Functional evaluation of pituitary reserve in patients with the amenorrhea-galactorrhea syndrome utilizing luteinizing hormone-releasing hormone (LH-RH), L-dopa and chlorpromazine. (1973) (40)
Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: Role of apoptosis (1994) (40)
Suppression of ovulation in the rat by an orally active antagonist of luteinizing hormone-releasing hormone. (1982) (40)
Production of Aldosterone by Rat Adrenal Glands in vitro.∗ † (1956) (39)
Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel (2007) (39)
Activity and specificity of synthetic thyrotropin-releasing hormone in man. (1970) (39)
Agonists of growth hormone-releasing hormone stimulate self-renewal of cardiac stem cells and promote their survival (2014) (39)
Influence of D-Trp-6-LH-RH on the survival time in patients with advanced pancreatic cancer. (1989) (39)
The distribution of radioactivity following the administration of labeled thyrotropin-releasing hormone (TRH) in rats and mice. (1971) (39)
Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: role of apoptosis. (1994) (39)
Brain cells as producers of releasing and inhibiting hormones. (1978) (39)
Protective effects of analogs of luteinizing hormone-releasing hormone against chemotherapy-induced testicular damage in rats. (1988) (39)
Influence of methionine-enkephalin and morphine on myoelectric activity of small bowel. (1980) (39)
Mammalian luteinizing hormone-releasing hormone induces ovulation in the domestic fowl. (1972) (39)
Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats (2001) (39)
MSH Activity in the Pituitaries of Rats Exposed to Constant Illumination (1967) (38)
Antagonists of growth hormone-releasing hormone cross the blood-brain barrier: a potential applicability to treatment of brain tumors. (2005) (38)
Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer (1999) (38)
Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone. (1983) (38)
Effects of the LHRH antagonist Cetrorelix on the brain function in mice (2009) (38)
Effect of testosterone and estradiol on the LH and FSH release induced by LH-releasing hormone (LH-RH) in intact male rats. (1972) (38)
GHRH antagonists support lung endothelial barrier function (2019) (38)
Localization of receptors for luteinizing hormone-releasing hormone in pancreatic and mammary cancer cells. (1991) (38)
Effect of Hypothalamic Extracts on Release of Growth Hormone in vitro ∗ (1965) (38)
Immunohistological detection of degenerating CRF-immunoreactive nerve fibers in the median eminence after lesion of paraventricular nucleus of the rat. A light and electron microscopic study (1983) (38)
Isolation, structural elucidation and synthesis of a tetradecapeptide with in vitro ACTH-releasing activity corresponding to residues 33-46 of the alpha-chain of porcine hemoglobin. (1978) (38)
Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition. (2009) (38)
Hypothalamic Somatostatin and LH-RH after Hypophysectomy, in Hyper- or Hypo-Thyroidism, and during Anesthesia in Rats (1978) (38)
Organ distribution of radioactivity and disappearance of radioactivity from plasma after administration of (3H) luteinizing hormone-releasing hormone to mice and rats. (1974) (38)
Antagonists of Growth Hormone-Releasing Hormone (2003) (37)
Immunomodulatory Action of Somatostatin (1987) (37)
Up-regulation of fibronectin and tissue transglutaminase promotes cell invasion involving increased association with integrin and MMP expression in A431 cells. (2010) (37)
Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue. (2005) (37)
MSH activity in pituitaries of rats treated with hypothalamic extracts from various animals. (1967) (37)
Localization of corticotropin-releasing factor-containing neurons in the brain of the domestic fowl (1984) (37)
Expression of gastrin releasing Peptide receptor in renal cell carcinomas: a potential function for the regulation of neoangiogenesis and microvascular perfusion. (2005) (37)
Effect of bombesin, gastrin‐releasing peptide (GRP)(14–27) and bombesin/GRP receptor antagonist RC‐3095 on growth of nitrosamine‐induced pancreatic cancers in hamsters (1993) (37)
Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations (2006) (37)
Prostate carcinoma tumor size in rats decreases after administration of antagonists of luteinizing hormone-releasing hormone. (1982) (37)
Neonatal administration of met-enkephalin facilitates maze performance of adult rats (1980) (37)
Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer. (2007) (37)
Gonadotrophin releasing hormone analogues. (1978) (37)
Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone‐releasing hormone antagonist cetrorelix (2010) (37)
Isolation and structure of several peptides from porcine hypothalami. (1980) (37)
Inhibitory effects of a luteinizing hormone‐releasing hormone agonist on basal and epidermal growth factor‐induced cell proliferation and metastasis‐associated properties in human epidermoid carcinoma a431 cells (2002) (36)
Ovulation Induced by Synthetic Luteinizing Hormone-Releasing Hormone in the Hamster (1971) (36)
Release of peptides from sustained delivery systems (microcapsules and microparticles) in vivo. A histological and immunohistochemical study. (2009) (36)
Uptake of iodinated luteinizing hormone releasing hormone analogs in the pituitary. (1977) (36)
CORTICOTROPIN-RELEASING FACTOR AND OTHER HYPOTHALAMIC PEPTIDES. (1964) (36)
Effects of antagonists of growth hormone-releasing hormone (GHRH) on GH and insulin-like growth factor I levels in transgenic mice overexpressing the human GHRH gene, an animal model of acromegaly. (1997) (36)
Antagonist of GH-releasing hormone receptors alleviates experimental ocular inflammation (2014) (36)
Androgen deficiency and dry eye syndrome in the aging male. (2014) (36)
Treatment of liver metastases of human colon cancers in nude mice with somatostatin analogue RC‐160 (1992) (36)
Isolation and structure of another hypothalamic peptide possessing MSH-release-inhibiting activity. (1972) (36)
Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice. (1999) (36)
Studies on the site of action of oral contraceptive steroids. II. Plasma LH and FSH levels after administration of antifertility steroids and LH-releasing hormone(LH-RH). (1970) (36)
Changes in subcellular distribution of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) after treatment with the LH-RH antagonist cetrorelix (2002) (36)
Stimulation of Prolactin and Growth Hormone Release by TRH Infused into a Hypophysial Portal Vessel 1 (1974) (36)
(D-Ala 6, Des-Gly-NH 2 10)-LH-RH-ethylamide: a new analogue with unusually high LH-RH-FSH-RH activity. (1974) (36)
Binding capacity of luteinizing hormone-releasing hormone and its analogues for pituitary receptor sites. (1977) (36)
Effect of Estradiol and Progesterone on the LH Release Induced by LH-Releasing Hormone (LH-RH) in Intact Diestrous Rats and Anestrous Ewes 1 (1972) (35)
Treatment of endometriosis with a delayed release preparation of the agonist D-Trp6-luteinizing hormone-releasing hormone: long-term follow-up in a series of 50 patients. (1990) (35)
Inhibition of the growth of caki‐I human renal adenocarcinoma in Vivo by luteinizing hormone‐releasing hormone antagonist cetrorelix, somatostatin analog RC‐160, and bombesin antagonist RC‐3940‐II (1998) (35)
Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone. (2005) (35)
Growth hormone releasing hormone (GHRH) signaling modulates intermittent hypoxia‐induced oxidative stress and cognitive deficits in mouse (2013) (35)
Growth hormone-releasing hormone and extra-pituitary tumorigenesis: therapeutic and diagnostic applications of growth hormone-releasing hormone antagonists (2003) (35)
Growth hormone-releasing hormone attenuates cardiac hypertrophy and improves heart function in pressure overload-induced heart failure (2017) (35)
Targeted therapy with a cytotoxic somatostatin analog, AN‐238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR‐1 (2005) (35)
Effect of septal lesions on plasma levels of MSH, corticosterone, GH and prolactin before and after exposure to novel environment: role of MSH in the septal syndrome. (1974) (35)
Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists (2000) (35)
Changes in serum luteinizing hormone folowing intraventricular and intravenous injections of luteinizing hormone-releasing hormone in the rat. (1972) (35)
Suppression of postovulatory gonadotropin levels does not affect corpus luteum function in rhesus monkeys. (1983) (35)
Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage. (2012) (35)
Gel filtration of posterior pituitary hormones. (1962) (35)
Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist (2013) (35)
Alteration of LH and FSH release in rats treated with clomiphene or its isomers. (1970) (35)
Ultrastructural observations of rat pituitary gonadotrophs following injection of purified porcine LH-RH. (1971) (34)
Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer. (1992) (34)
RAPID COMMUNICATION: Human Ovarian Cancers Express Somatostatin Receptors (2000) (34)
Immunocytochemical localization of corticotropin releasing factor (CRF)-like immunoreactivity in the thalamus of the rat (1984) (34)
Inhibition of growth of the human malignant glioma cell line (U87MG) by the steroid hormone antagonist RU486. (1993) (34)
Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix. (2001) (34)
Melanocyte-stimulating and corticotrophic activities in human foetal pituitary glands. (1968) (34)
Control of gonadotrophic hormone release in trout: influence of synthetic LH-RH and LH-RH analogues in vivo and in vitro. (1981) (34)
Antagonist of growth hormone-releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway. (2005) (34)
LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy. (2007) (34)
Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75). (1994) (34)
Dose‐dependent growth inhibition in vivo of PC‐3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ‐J‐7‐138 (2008) (34)
Suppression of growth of H‐69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling (2004) (34)
Studies on the Thyrotropin-Releasing Hormone (TRH)∗ Activity in Peripheral Blood† (1969) (34)
Naloxone-like actions of MIF-1 do not require the presence of the pituitary (1980) (34)
Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins. (2005) (33)
Complete regression of MX‐1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone–releasing hormone, AN‐207 (1999) (33)
Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines. (1998) (33)
A peptide inhibitor of luteinizing hormone-releasing hormone (LH-RH). (1973) (33)
Further observations on the therapy of anovulatory infertility with synthetic luteinizing hormone-releasing hormone. (1974) (33)
Dose-response relationship of luteinizing hormone to luteinizing hormone--releasing hormone in man. (1971) (33)
The Effects of MSH and MIF on the Brain (1975) (33)
Activity of VIP, somatostatin and other peptides in the mouse vas deferens assay (1978) (33)
Radioimmunoassay for octapeptide analogs of somatostatin: measurement of serum levels after administration of long-acting microcapsule formulations. (1988) (33)
Study on the recovery of pituitary function during puerperium using synthetic LRH. (1974) (33)
New treatment approaches for prostate cancer based on peptide analogues. (2008) (33)
Investigation of the role of tryptophan in the luteinizing hormone-releasing hormone. (1974) (33)
Isolation and characterization of adrenocortical progenitors involved in the adaptation to stress (2018) (32)
Isolation of growth hormone-releasing hormone(GRH) from porcine hypothalami. (1969) (32)
Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition (2009) (32)
Use of radioreceptor assay and cell superfusion system for in vitro screening of analogs of growth hormone-releasing hormone. (1993) (32)
Isolation and amino acid sequence of corticotropin-releasing factor from pig hypothalami. (1985) (32)
Electron microscope studies of somatotrophs of rat pituitary after injection of purified growth hormone releasing factor (GRF). (1969) (32)
Saturable efflux of the peptides RC-160 and Tyr-MIF-1 by different parts of the blood-brain barrier (1994) (32)
Neonatal corticoid administration: effects upon adult pituitary growth hormone and hypothalamic growth hormone-releasing hormone activity. (1969) (32)
Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro. (2000) (32)
Studies on the inhibition of pancreatic secretion by luminal somatostatin. (1981) (32)
Targeting of Peptide Cytotoxins to LHRH Receptors For Treatment of Cancer. (2016) (32)
Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel (2006) (32)
Pituitary Response to Synthetic LH-RH in Stein-Leventhal Syndrome and Functional Amenorrhea (1973) (32)
Multimodal Somatostatin Receptor Theranostics Using [64Cu]Cu-/[177Lu]Lu-DOTA-(Tyr3)octreotate and AN-238 in a Mouse Pheochromocytoma Model (2016) (32)
Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors (2008) (32)
Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer (2014) (32)
Anovulatory effect of a LHRH antagonist in women. (1981) (32)
Failure to interrupt established pregnancy in humans by D-tryptophan-6-luteinizing hormone-releasing hormone. (1981) (32)
Synthetic thyrotropin-releasing hormone. Activity in men and women, specificity of action, inhibition by triiodothyronine, and activity orally. (1971) (32)
Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog. (2005) (32)
Beneficial effects of novel antagonists of GHRH in different models of Alzheimer's disease (2012) (31)
Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild‐type p53 and decrease in p21 and mutant p53 proteins (2012) (31)
Immunohistochemical detection of GHRH and its receptor splice variant 1 in primary human breast cancers. (2004) (31)
Expression of growth hormone-releasing hormone (GHRH) and splice variant of GHRH receptors in normal mouse tissues (2006) (31)
NEUROHUMORAL FUNCTIONS OF THE HYPOTHALAMUS. (1964) (31)
Inhibition of MSH Release in Frogs by Direct Application of L-Prolyl-L-leucylglycinamide to the Pituitary 1 (1971) (31)
Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers. (2013) (31)
Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 (AEZS-108) (2012) (31)
Protective effects of agonists of growth hormone-releasing hormone (GHRH) in early experimental diabetic retinopathy (2017) (31)
Synthesis and relationship of L-glutaminyl-L-histidyl-L-prolinamide to the thyrotropin releasing hormone. (1970) (31)
Inhibition of growth of MDA‐MB‐468 estrogen‐independent human breast carcinoma by bombesin/gastrin‐releasing peptide antagonists RC‐3095 and RC‐3940‐II (2000) (31)
Luteolytic effect of D-Trp6-luteinizing hormone-releasing hormone in the rhesus monkey (Macaca mulatta). (1981) (31)
Inhibition of proliferation of PC‐3 human prostate cancer by antagonists of growth hormone–releasing hormone: Lack of correlation with the levels of serum IGF‐I and expression of tumoral IGF‐II and vascular endothelial growth factor (2002) (31)
Correlation between the effects of bombesin antagonists on cell proliferation and intracellular calcium concentration in Swiss 3T3 and HT-29 cell lines. (1996) (31)
The micro estimation of steroids produced by rat adrenals in vitro. (1954) (31)
Pseudononapeptide bombesin antagonists containing C-terminal Trp or Tpi (1992) (31)
Purification of hypothalamic releasing hormones of human origin. (1970) (31)
Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats. (2004) (31)
Serum LH levels in prepubertal female pigs chronically treated with synthetic luteinizing hormone-releasing hormone-follicle stimulating hormone-releasing hormone (LH-RH-FSH-RH). (1973) (31)
Activation of mitogen-activated protein kinases by a splice variant of GHRH receptor. (2010) (31)
Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth (2017) (31)
Luteinizing hormone-releasing hormone analogs with increased anti-ovulatory activity. (1981) (31)
Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study. (2006) (31)
Magnetoelectric nanoparticles for delivery of antitumor peptides into glioblastoma cells by magnetic fields. (2018) (31)
Serum Levels of Prolactin and Luteinizing Hormone (LH) in the Ewe at Various Stages of the Estrous Cycle 1 (1970) (31)
Inhibition of growth of a prolactin-secreting pituitary tumor in rats by analogs of luteinizing hormone-releasing hormone and somatostatin. (1983) (31)
Targeting the 5′-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer (2015) (30)
Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer. (2015) (30)
Effect of simple amino acid replacements on the biological activity of luteinizing hormone-releasing hormone. (1973) (30)
Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH) (2012) (30)
Effects of α- and β-Melanocyte Stimulating Hormones and Other Peptides on the Thyroid in Mice (1964) (30)
Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75. (1991) (30)
Stimulation of luteinizing hormone (LH) and follicle-stimulating hormone by (D-Leu6, des-Gly10-NH2)-LH-releasing hormone ethylamide after subcutaneous, intravaginal, and intrarectal administration to women. (1977) (30)
Targeted cytotoxic analog of luteinizing hormone‐releasing hormone AN‐207 inhibits the growth of PC‐82 human prostate cancer in nude mice (1999) (30)
Effect of thyrotropin-releasing factor in man. (1968) (30)
STIMULATION OF RELEASE OF FOLLICLE-STIMULATING HORMONE BY HYPOTHALAMIC EXTRACTS IN VITRO AND IN VIVO. (1965) (30)
DISAPPEARANCE OF LH‐RELEASING HORMONE IN MAN AS DETERMINED BY RADIOIMMUNOASSAY (1974) (30)
Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer. (1994) (30)
Effect of Synthetic Hypothalamic Gonadotropin-Releasing Hormone (FSH/LH-RH) in Anovulatory Sterility* (1974) (30)
Antagonists of growth hormone-releasing hormone inhibit proliferation induced by inflammation in prostatic epithelial cells (2017) (30)
Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75). (1991) (30)
Inhibition of PC‐3 human prostate cancers by analogs of growth hormone‐releasing hormone (GH‐RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity (2002) (30)
A correlation of endocrine and anticancer effects of some antagonists of GHRH (2010) (30)
Alterations of tumor microenvironment by nitric oxide impedes castration-resistant prostate cancer growth (2018) (30)
Therapeutic effect of synthetic luteinizing hormone-releasing hormone (LH-RH) in male infertility due to idiopathic azoospermia and oligospermia. (1973) (30)
Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model. (1985) (30)
Inhibitory effect of somatostatin analogue RC-160 on the growth of hepatic metastases of colon cancer in rats: a study with magnetic resonance imaging. (1992) (30)
Synthesis and biological activity of LH-RH antagonists modified in position 1 (1982) (30)
Reduction of LH-RH pituitary and estradiol uterine binding sites by a superactive analog of luteinizing hormone-releasing hormone. (1980) (30)
Immunohistochemical localization of somatostatin in endocrine cells of the rat stomach (1976) (29)
Purification of thyrotropic hormone-releasing factor from bovine hypothalamus. (1966) (29)
The antigenic determinant of the LH-releasing hormone for three different antisera. (1975) (29)
Transplantation of pancreatic islets to adrenal gland is promoted by agonists of growth-hormone-releasing hormone (2013) (29)
Transcriptional Activation of Mouse sst2 Somatostatin Receptor Promoter by Transforming Growth Factor-β (2001) (29)
Antagonists of growth hormone-releasing hormone receptor induce apoptosis specifically in retinoblastoma cells (2016) (29)
Dissociation of MSH and ACTH release in man. (1973) (29)
Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt (2007) (29)
Growth Hormone–Releasing Hormone Agonists Reduce Myocardial Infarct Scar in Swine With Subacute Ischemic Cardiomyopathy (2015) (29)
Luteinizing hormone-releasing hormone as an autocrine growth factor in ES-2 ovarian cancer cell line. (2000) (29)
Beneficial effects of growth hormone-releasing hormone agonists on rat INS-1 cells and on streptozotocin-induced NOD/SCID mice (2015) (29)
Delayed Implantation Caused by Administration of Sheep Immunogamma Globulin against LHRH in the Rat 1 (1976) (29)
Novel antagonists of growth hormone‐releasing hormone inhibit growth and vascularization of human experimental ovarian cancers (2012) (29)
Response of patients with advanced prostatic cancer to administration of somatostatin analog RC‐160 (vapreotide) at the time of relapse (2003) (29)
Effect of actinomycin D on the inhibitory response of estrogen on LH release. (1969) (29)
Endocrine, Gastrointestinal, and Antitumor Activity of Somatostatin Analogues (1986) (29)
Stimulation of Thyrotropin (TSH) Secretion by TSH-Releasing Factor (TRF) in Organ Cultures of Anterior Pituitary∗ (1969) (28)
Releasing factors in human hypothalamic and neurohypophysial extracts. (1967) (28)
Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D‐Trp‐6‐LH‐RH (1988) (28)
Electrophysiological correlates of melanocyte-stimulating hormone activity in the frog. (1972) (28)
Selective coupling of methotrexate to peptide hormone carriers through a gamma-carboxamide linkage of its glutamic acid moiety: benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate activation in salt coupling. (1993) (28)
Receptors for Luteinizing Hormone Releasing Hormone Expressed on Human Renal Cell Carcinomas Can Be Used for Targeted Chemotherapy with Cytotoxic Luteinizing Hormone Releasing Hormone Analogues (2005) (28)
MSH activity in pituitary glands of rats treated with tranquilizing drugs. (1966) (28)
Targeted cytotoxic somatostatin analogs: A modern approach to the therapy of various cancers (2001) (28)
Effect of administration of anti-serum to luteinizing hormone-releasing hormone on gonadal function during the estrous cycle in the hamster. (1976) (28)
Effect of actinomycin D on hormones that control the release of thyrotropin from the anterior pituitary glands of mice. (1968) (28)
Effect of intraventricular administration of anti-somatostatin gamma-globulin on the lethal dose-50 of strychnine and pentobarbital in rats. (1978) (28)
Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice. (1994) (28)
Antagonists of growth hormone‐releasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells (2010) (27)
Decrease in the AgNOR number in Dunning R3327 prostate cancers after treatment with an agonist and antagonist of luteinizing hormone-releasing hormone. (1991) (27)
Inhibition of growth of experimental prostate cancer in rats by LH‐RH analogs linked to cytotoxic radicals (1993) (27)
Growth hormone releasing hormone induces the expression of nitric oxide synthase (2010) (27)
Effect of thyrotropin releasing factor (TRF) of ovine, bovine, porcine and human origin on thyrotropin release in vitro and in vivo. (1965) (27)
Somatostatin analog RC‐160 inhibits growth of CFPAC‐1 human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine monophosphate (1995) (27)
The effects of an LH-RH antagonist ([N-Ac-D-Trp(1)(3), D-p-Cl-Phe(2), D-Phe(6), D-Ala(10)]-LH-RH) during the preovulatory period of the rhesus monkey. (1981) (27)
Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207. (2002) (27)
A clinical overview of carcinoid tumors: perspectives for improvement in treatment using peptide analogs (review). (2005) (27)
Cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH): A new approach to targeted chemotherapy (2002) (27)
Termination of pregnancy by sheep anti-LHRH gamma globulin in rats. (1976) (27)
Targeted chemotherapy with cytotoxic bombesin analogue AN‐215 inhibits growth of experimental human prostate cancers (2006) (27)
Purification of follicle-stimulating hormone-releasing factor (FSH-RF) from bovine hypothalamus. (1966) (27)
Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice. (1994) (27)
Effect of atrial natriuretic peptide on gonadotropin release in superfused rat pituitary cells. (1986) (27)
Behavioral effects of centrally administered LH-RH agonist in rats (1992) (27)
Mechanisms of synergism between antagonists of growth hormone‐releasing hormone and antagonists of luteinizing hormone‐releasing hormone in shrinking experimental benign prostatic hyperplasia (2013) (27)
Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207. (2005) (27)
Follicular stimulation by chronic treatment with synthetic LH-releasing hormone in hypophysectomized female rats bearing pituitary grafts. (1973) (27)
Regulation of Vascular Calcification by Growth Hormone–Releasing Hormone and Its Agonists (2018) (27)
Methionine-Enkephalin Stimulates Gastric Secretion and Gastric Mucosal Blood Flow (1978) (27)
Polyfluoroalkylamine derivatives of luteinizing hormone-releasing hormone. (1975) (27)
Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS‐related diarrhoeal diseases (1992) (27)
Gonadotropin-releasing activity of two highly active and long-acting analogs of luteinizing hormone-releasing hormone after subcutaneous, intravaginal, and oral administration. (1975) (27)
Inhibition of the pituitary-gonadal axis in nude male mice by continuous administration of LHRH agonists and antagonists. (1990) (27)
Antagonistic analogs of growth hormone releasing hormone (GHRH) inhibit cyclic AMP production of human cancer cell lines in vitro☆ (1999) (27)
Development of radioimmunoassay for a potent luteinizing hormone-releasing hormone antagonist. Evaluation of serum levels after injection of [Ac-3-(2-naphthyl)-D-Ala1, D-Phe(pCl)2, 3-(3-pyridyl)-D-Ala3, D-Cit6, D-Ala10] LHRH. (1990) (26)
Corticotropin releasing activity of lysine vasopressin analogues. (1969) (26)
Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin. (1997) (26)
Inhibition of luteinizing hormone release by analogs of luteinizing hormone-releasing hormone (LHRH) in vitro. (1976) (26)
Purification and in vivo and in vitro studies with porcine luteinizing hormone-releasing factor (LRF). (1967) (26)
Re-examination of porcine and bovine hypothalamic fractions for additional luteinizing hormone and follicle stimulating hormone-releasing activities. (1976) (26)
Paradoxical effects of D-Trp6-luteinizing hormone-releasing hormone on the hypothalamic-pituitary-gonadal axis in immature female rats. (1979) (26)
Lack of effect of steroids on thyrotropin-releasing hormone (TRH) mediated thyrotropin (TSH) release in man. (1973) (26)
Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: mechanisms of action. (1996) (26)
Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function (2014) (26)
Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis. (1997) (26)
Treatment with luteinizing-hormone-releasing hormone antagonist sb-75 decreases levels of epidermal growth-factor receptor and its messenger-RNA in ov-1063 human epithelial ovarian-cancer xenografts in nude-mice. (1994) (26)
Effect of Pentobarbital and Ether Stress on Serum Prolactin Levels in Rats 1 (1971) (26)
Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins. (2006) (26)
Treatment of idiopathic normogonadotropic oligoasthenospermia with synthetic luteinizing hormone-releasing hormone. (1976) (26)
Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN‐215) and a bombesin antagonist (RC‐3095) (2010) (26)
Growth hormone-releasing hormone antagonist induces apoptosis of human endometrial cancer cells through PKCδ-mediated activation of p53/p21. (2010) (26)
Receptors for d-Trp6-Luteinizing Hormone-Releasing Hormone, Somatostatin, and Insulin-Like Growth Factor I in MXT Mouse Mammary Carcinoma (1989) (26)
In vitro Studies with Thyrotropin Releasing Factor.∗ (1966) (26)
Effects of the growth hormone-releasing hormone (GH-RH) antagonist on brain functions in mice (2011) (26)
Aspects of hypothalamic regulation of the pituitary gland. Its implications for the control of reproductive processes. (1980) (26)
Mini-Review: Novel Therapeutic Strategies to Blunt Actions of Pneumolysin in the Lungs (2013) (26)
Expression of growth hormone-releasing hormone in human primary endometrial carcinomas. (2002) (26)
Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice (2000) (26)
Discovery of LHRH and development of LHRH analogs for prostate cancer treatment (2017) (26)
Bombesin may stimulate proliferation of human pancreatic cancer cells through an autocrine pathway. (1996) (26)
Extinction of an appetitive operant response after administration of MSH. (1974) (26)
Apoptosis Versus Necrosis: Which Should Be the Aim of Cancer Therapy? (1999) (25)
HYPOTHALAMIC HORMONE INTERACTION IN ACROMEGALY (1975) (25)
Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207. (2005) (25)
Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation. (2012) (25)
LH Release by LH-Releasing Hormone in Golden Hamsters at Various Stages of Estrous Cycle 1 (1972) (25)
Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma (2019) (25)
Histological changes in dunning prostate tumors and testes of rats treated with LH‐RH antagonist SB‐75 (1991) (25)
The disappearance, excretion, and metabolism of tritiated prolyl-leucyl-glycinamide in man. (1974) (25)
Advanced ovarian carcinoma: response to the agonist D-Trp-6-LHRH. (1985) (25)
Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215 (2002) (25)
Effects of the LHRH antagonist Cetrorelix on affective and cognitive functions in rats (2010) (25)
EFFECT OF THYROXINE ON THE INACTIVATION OF THYROTROPHIN‐RELEASING HORMONE BY RAT AND HUMAN PLASMA (1976) (25)
Growth hormone‐releasing hormone antagonists reduce prostatic enlargement and inflammation in carrageenan‐induced chronic prostatitis (2018) (24)
Gonadotropin-secreting pituitary adenoma with concomitant hypersecretion of testosterone and elevated sperm count. Treatment with LRH agonist. (1986) (24)
Growth Hormone-Releasing Hormone Receptor Antagonist Modulates Lung Inflammation and Fibrosis due to Bleomycin (2019) (24)
Syntheses and LH- and FSH-RH activities of LH-RH analogs substituted at position 8. (1972) (24)
Antinflammatory, antioxidant, and behavioral effects induced by administration of growth hormone-releasing hormone analogs in mice (2020) (24)
Effects of β-(Tyr9)melantropin-(9–18) decapeptide on passive and active avoidance behavior and on open-field activity of rats (1981) (24)
Effect of microcapsules of luteinizing hormone‐releasing hormone antagonist SB‐75 and somatostatin analog RC‐160 on endocrine status and tumor growth in the dunning R‐3327H rat prostate cancer model (1992) (24)
Possible aminergic mediation of MSH release and of the CNS effects of MSH and MIF-I. (1980) (24)
Structure and synthesis of the thyrotropin-releasing hormone. (1971) (24)
Partial reversibility of growth hormone (GH) deficiency in the GH-releasing hormone (GHRH) knockout mouse by postnatal treatment with a GHRH analog. (2005) (24)
Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors. (2004) (24)
Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness. (2001) (24)
Treatment of advanced prostatic carcinoma with D‐trp‐6‐LH‐RH (1984) (24)
Increased release of LH after administration of LH-RH to men pretreated with clomiphene. (1970) (24)
Agonists of luteinizing hormone-releasing hormone in prostate cancer (2013) (24)
Transcriptional activation of mouse sst2 somatostatin receptor promoter by transforming growth factor-beta. Involvement of Smad4. (2000) (24)
Somatostatin analog RC‐160 inhibits the growth of human osteosarcomas in nude mice (1996) (24)
Activation of Janus kinase/signal transducer and activator of transcription 3 pathway by growth hormone-releasing hormone (2010) (24)
Effect of infusion of hypothalamic extracts on serum prolactin levels in rats treated with nembutal, CNS depressants or bearing hypothalamic lesions. (1972) (24)
Prolonged suppression of plasma LH levels in male rats after a single injection of an LH-RH agonist in poly(DL-lactide-co-glycolide) microcapsules. (1985) (24)
Luteinizing hormone releasing hormone. Solid-phase synthesis of a 5-phenylalanine analog possessing high biological activity. (1973) (23)
The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA‐PCa‐2b and LuCaP‐35 prostate cancers (2007) (23)
Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers (2012) (23)
Characterization of the Hormonal Responses to Luteinizing Hormone-Releasing Hormone (LH-RH) in Prepubertal and Adult Subjects (1972) (23)
Relative insensitivity of rhesus monkeys to the LH-releasing hormone (LH-RH). (1973) (23)
Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix. (2000) (23)
Induction of ovulation in rats by highly purified pig LH-releasing factor (LRF). (1967) (23)
Effect of actinomycin D on the pituitary response to LH-RH. (1975) (23)
Synthesis and biological activities of analogs of luteinizing hormone-releasing hormone (LH-RH) substituted in position 1 or 2. (1973) (23)
Suppression of somatostatin levels in the hepatic portal and systemic plasma of the rat by synthetic human pancreatic polypeptide. (1979) (23)
Responsiveness of the hamster pancreatic cancer to treatment with microcapsules of D-Trp-6-LH-RH and somatostatin analog RC-160 (1989) (23)
Neurotransmission of the antidepressant-like effects of the growth hormone-releasing hormone antagonist MZ-4-71 (2012) (23)
Long-term effect of D-Trp6-luteinizing hormone-releasing hormone on testicular size and luteinizing hormone, follicle-stimulating hormone, and testosterone levels in hypothalamic hypogonadotropic males. (1981) (23)
Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin analogue AN-238. (2005) (23)
Prolonged inhibition of luteinizing hormone and testosterone levels in male rats with the luteinizing hormone-releasing hormone antagonist SB-75. (1990) (23)
Ultrastructural and light microscopic observations of rat pituitary LH-containing gonadotrophs following injection of synthetic LH-RH. (1973) (23)
Effect of somatostatin on gastrointestinal secretions and peptic ulcer production in cats. (1977) (23)
Prevention of implantation by [D-Trp6-LH-RH in the rat: comparative study with the effects of large doses of HCG on pregnancy. (1977) (23)
In vitro inhibition of LH release by a synthetic antagonist of LH-releasing hormone (LH-RH). (1974) (23)
Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. (2010) (23)
Superactive octapeptide somatostatin analogs containing tryptophan at position 1. (1987) (23)
GHRH antagonist MZ-5-156 increases the expression of AMPK in A549 lung cancer cells (2011) (22)
Isolation of porcine GH release inhibiting hormone (GH RIH): the existence of 3 forms of GH RIH (1975) (22)
Effect of luteinizing hormone‐releasing hormone analogs containing cytotoxic radicals on growth of estrogen‐independent MXT mouse mammary carcinoma in vivo (1992) (22)
Regulation of prostate‐specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone‐releasing hormone and vasoactive intestinal peptide (2001) (22)
Treatment of prostatic carcinoma with D‐Trp‐6‐LH‐RH: Plasma hormone levels after daily subcutaneous injections and periodic administration of delayed‐release preparations (1985) (22)
Analogs of luteinizing hormone-releasing hormone containing derivatives of phenylalanine in place of tyrosine. (1973) (22)
Endocrine and antineoplastic actions of growth hormone-releasing hormone antagonists. (2008) (22)
Suppression of tumor growth by growth hormone-releasing hormone antagonist JV-1-36 does not involve the inhibition of autocrine production of insulin-like growth factor II in H-69 small cell lung carcinoma. (2000) (22)
An in vivo assay for anti-LH-RH and anti-FSH-RH activity of inhibitory analogues of LH-RH. (1975) (22)
Chapter 8: Clinical Effects of Hypothalamic‐Pituitary Peptides on the Central Nervous System (1978) (22)
Radioautographic localization of radioactivity in rat brain after intraventricular or intracarotid injection of 3H-L-prolyl-L-leucyl glycinamide (1975) (22)
Inhibition of human endometrial cancer cell growth in vitro and in vivo by somatostatin analog RC-160. (1999) (22)
Characteristics of the plasma disappearance of (3H)-thyrotropin-releasing hormone in the rat. (1974) (22)
Therapeutic hypogonadism induced by a delayed-release preparation of microcapsules of D-Trp-6-luteinizing hormone-releasing hormone: a preliminary study in eight women with endometriosis. (1986) (22)
Growth hormone-releasing activity in the hypothalamus of animals of different species. (1967) (22)
Human ovarian cancers express somatostatin receptors. (2000) (22)
Specific cleavage of C-methionyl peptide bonds in hydrogen fluoride. (1964) (22)
Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system (2004) (22)
Synthesis and biological properties of the 2-L-beta-(pyrazolyl-1)alanine analogs of luteinizing hormone-releasing hormone and thyrotropin-releasing hormone. (1975) (22)
Inhibition of growth and reduction in tumorigenicity of UCI-107 ovarian cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide (2001) (22)
Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities. (2006) (22)
ATROPINE SELECTIVELY BLOCKS GHRH‐INDUCED GH SECRETION WITHOUT ALTERING LH, FSH, TSH, PRL AND ACTH/CORTISOL SECRETION ELICITED BY THEIR SPECIFIC HYPOTHALAMIC RELEASING FACTORS (1986) (22)
Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 (2002) (22)
Rhenium-labeled somatostatin analog RC-160. 1H NMR and computer modeling conformational analysis. (1994) (21)
GHRH antagonist inhibits focal adhesion kinase (FAK) and decreases expression of vascular endothelial growth factor (VEGF) in human lung cancer cells in vitro (2012) (21)
Stimulated release of hypothalamic growth hormone-releasing activity by morphine and pentobarbital (1977) (21)
GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer (2012) (21)
Agonistic analogs of growth hormone releasing hormone (GHRH) promote wound healing by stimulating the proliferation and survival of human dermal fibroblasts through ERK and AKT pathways (2016) (21)
Release and Synthesis of Luteinizing Hormone and Follicle-Stimulating Hormone in Pituitary Cultures in Response to Hypothalamic Preparations (1970) (21)
Splice variant of growth hormone-releasing hormone receptor drives esophageal squamous cell carcinoma conferring a therapeutic target (2020) (21)
Long-term use of an LH-RH agonist in the management of uterine leiomyomas: a study of 17 cases. (1989) (21)
Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels (2014) (21)
ACTH content of rat pituitary glands. (1956) (21)
Studies on dose response relationship of luteninizing hormone-releasing hormone (LH-RH) in sheep. (1970) (21)
The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma. (2010) (21)
Studies on the site of action of oral contraceptive steroids. I. Effect of antifertility steroids on plasma LH levels and on the response to luteinizing hormone-releasing factor in rats. (1968) (21)
New antagonists of bombesin gastrin-releasing Peptide with C-terminal leu-psi-(ch2n)tac-nh2. (1995) (21)
Increased and prolonged LH-RH/FSH-RH activity of synthetic (D-Ala6, Des-Gly-NH210)-LH-RH-ethylamide in normal women. (1975) (21)
Immunoreactive somatostatin in human pancreatic secretion. (1981) (21)
Inhibition by six somatostatin analogs of plasma growth hormone levels stimulated by thiamylal and morphine in the rat (1976) (21)
Phase II trial with D‐Trp‐6‐LH‐RH in prostatic carcinoma: Comparison with other hormonal agents (1986) (21)
Effective treatment of advanced estrogen–independent MXT mouse mammary cancers with targeted cytotoxic LH–RH analogs (1999) (21)
Profound Actions of an Agonist of Growth Hormone–Releasing Hormone on Angiogenic Therapy by Mesenchymal Stem Cells (2016) (21)
Comparison of the Effects of Subcutaneous and Intravenous Injection of Synthetic LH-Releasing Hormone (LH-RH) on Serum LH and FSH Levels in Men1 (1973) (21)
Bombesin may stimulate proliferation of human pancreatic cancer cells through an autocrine pathway (1996) (21)
Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition (2009) (21)
Melanin in the rat brain (1976) (21)
Inhibition of the UCI‐107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN‐238 (2001) (21)
Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone. (2005) (21)
Inhibition of Growth of Experimental Human and Hamster Pancreatic Cancers In Vivo by a Targeted Cytotoxic Bombesin Analog (2005) (21)
Growth hormone-releasing hormone stimulates cAMP release in superfused rat pituitary cells. (1995) (20)
Synthesis and biological properties of ovine corticotropin-releasing factor (CRF). (1982) (20)
A Phase II Trial of AEZS‐108 in Castration‐ and Taxane‐Resistant Prostate Cancer (2017) (20)
Effects of chronic treatment with LH-FSH-RH in hypophysectomized pituitary-grafted male rats. (1973) (20)
New pseudononapeptide bombesin antagonists with C-terminal leu-psi(ch2n)tac-nh2 show high binding-affinity to bombesin/grp receptors on cfpac-1 human pancreatic-cancer cells. (1995) (20)
Effects of Cyclic Hexapeptide Analog of Somatostatin on Pancreatic Secretion in Dogs (1985) (20)
Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238. (2003) (20)
[Phe4]somatostatin: a potent, selective inhibitor of growth hormone release. (1980) (20)
Ultrastructural characteristics of immunolabelled, corticotropin releasing factor (CRF)-synthesizing neurons in the rat brain (2004) (20)
Inhibition of the postcastration rise of luteinizing hormone and follicle-stimulating hormone in female rhesus monkeys (Macaca mulatta) by the administration of a luteinizing hormone-releasing hormone inhibitory analog ([N-Ac-D-Trp1-3,D-p-Cl-phe2,D-Phe6,D-Ala10]-LH-RH). (1981) (20)
Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice. (1999) (20)
Ontogenetic development of corticotropin-releasing factor (CRF)-containing neural elements in the brain of the chicken during incubation and after hatching (1986) (20)
Inhibition of Gonadotropin Release in Chimpanzees by the LH-RH Antagonist (D-Phe2, D-Trp3, D-Phe6)-LH-RH (1979) (20)
Inhibition of pituitary-gonadal axis in mice by long-term administration of D-Trp-6-LHRH microcapsules. (1989) (20)
Effect of Somatostatin Analogs on Gastric and Pancreatic Secretion 1 (1977) (20)
Ultrastructural observations of granule extrusion from rat anterior pituitary cells after injection of LH-releasing hormone (2004) (20)
Serum gonadotropin concentrations and ovarian response in ewes treated with analogs to LH-RH/FSH-RH. (1976) (20)
GH-RH antagonist (MZ-4-71) inhibits VEGF secretion and proliferation of murine endothelial cells. (2003) (20)
Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone. (2007) (19)
High molecular weight peptide with corticotropin-releasing factor activity from porcine hypothalami. (1981) (19)
Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway (2010) (19)
Anti-inflammatory effects of α-MSH through p-CREB expression in sarcoidosis like granuloma model (2020) (19)
Hormonal manipulation of benign prostatic hyperplasia (2013) (19)
Plasma growth hormone response to synthetic GH-RH1-44 in 52 children and adults with growth hormone deficiency of various etiologies. (1985) (19)
Structure‐activity relationships of eighteen somatostatin analogues on gastric secretion. (1978) (19)
Failure of putrescine and other polyamines to promote FSH release in vitro. (1970) (19)
Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH (2018) (19)
Effective Inhibition of Experimental Human Ovarian Cancers with a Targeted Cytotoxic Bombesin Analogue AN-215 (2005) (19)
Cyclic analogues of luteinizing hormone-releasing hormone with significant biological activities. (1978) (19)
Effect of Histamine, Hog Vasopressin, and Corticotropin-Releasing Factor (GRF) on AGTH Release in vitro (1956) (19)
Absence of suppressive effect of somatostatin on prolactin levels in patients with hyperprolactinemia. (1987) (19)
Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238. (2004) (19)
Re-evaluation of a technique of pituitary incubation in vitro as an assay for corticotropin releasing factor. (1959) (19)
CARDIOVASCULAR ACTIONS OF MELANOCYTE-STIMULATING HORMONE IN THE DOG (1973) (19)
D-Trp-6-luteinizing hormone-releasing hormone inhibits hyperprolactinemia in female rats. (1985) (19)
Disappearance and excretion of labeled α-MSH in man (1978) (19)
Gonadotropin releasing hormone (GnRH): neuropharmacological studies. (1975) (19)
Blockade of LH release and ovulation in the rabbit with inhibitory analogues of luteinizing hormone releasing hormone. (1977) (19)
A conjugate of doxorubicin and an analog of Luteinizing Hormone-Releasing Hormone shows increased efficacy against oral and laryngeal cancers. (2002) (19)
Serum LH, FSH and testosterone response to the administration of a new LH-RH analog, D-Trp6-LH-RH, in normal men. (1977) (19)
Stress-inducible-stem cells: a new view on endocrine, metabolic and mental disease? (2018) (19)
Distribution of radioactivity in the organs of the rat and mouse after injection of L-(3H)prolyl-L-leucyl-glycinamide. (1975) (19)
Suppressive effect of an inhibitory LHRH analog on the gonadotropin response to LHRH in normal women. (1980) (19)
Involvement of the unfolded protein response in the protective effects of growth hormone releasing hormone antagonists in the lungs (2020) (18)
Absence of luteinizing hormone-releasing hormone (LH-RH) from catecholaminergic neurons. (1975) (18)
Antiproliferative actions of growth hormone-releasing hormone antagonists on MiaPaCa-2 human pancreatic cancer cells involve cAMP independent pathways (2001) (18)
The Role of the FSH System in the Development and Progression of Prostate Cancer (2014) (18)
Structure of a hypothalamic peptide possessing gonadotropin-releasing activity. (2009) (18)
Mass action-type direct feedback control of pituitary release. (1971) (18)
Changing immunoreactivity of the LHRH-containing nerve terminals in the organon vasculosum of the lamina terminalis. (1976) (18)
Comparison of the anti-LH/FSH-RH and anti-ovulatory activities of (D-Phe2, D-Leu6)-LH-RH and (D-Phe2, D-Ala6)-LH-RH. (1976) (18)
New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor (2015) (18)
Antifertility effects of a potent LH-RH antagonist in male and female rats. (1986) (18)
An in vivo assay for thyrotropin releasing factor. (1966) (18)
The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines. (2011) (18)
Antioxidant activity of vasoactive intestinal peptide in HK2 human renal cells (2012) (18)
Branched-chain analogues of luteinizing hormone-releasing hormone. (1978) (18)
Biological Activity and Receptor Binding Characteristics to Various Human Tumors of Acetylated Somatostatin Analogs (1992) (18)
Behavioral and hormonal effects of prolonged high doses of LHRH in male impotency (1981) (18)
Inhibition of experimental small‐cell and non‐small‐cell lung cancers by novel antagonists of growth hormone‐releasing hormone (2018) (18)
Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin (2008) (18)
The Effect of Oral and Vaginal Administration of Synthetic LH-RH and [D-ALA6, DES GLY10-NH2]-LH-RH Ethylamide on Serum LH Levels in Ovariectomized, Steroid Blocked Rats 1 (1975) (18)
Somatostatin and its analog enhance the formation of human leukocyte migration inhibiting factor: Further evidence for immunomodulatory action of somatostatin (1987) (18)
Expression of growth hormone–releasing hormone receptor splice variant 1 in primary human melanomas (2008) (18)
RECENT ADVANCES IN HUMAN REPRODUCTION (1976) (18)
Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124] (2013) (18)
The effect of GHRH antagonists on human glioblastomas and their mechanism of action (2010) (18)
Blockade of ovulation in rats by inhibitory analogs of luteinizing hormone-releasing hormone (1976) (18)
MSH Activity in Pituitaries of Rats Exposed to Stress (1967) (18)
A microencapsulated analog of LH-RH accelerates maturation but without stimulating sex reversal in the protandrous black porgy, Acanthopagrus schlegeli. (1995) (18)
Inhibition of GH Release in Rats by New Potent Antagonists of Growth Hormone-Releasing Hormone (GH-RH) (1997) (17)
Vapreotide labeled with Tc-99m for imaging tumors. (1996) (17)
Peptides and the Blood-Brain Barrier (1980) (17)
Immunohistochemical localization of luteinizing hormone-releasing hormone (LH-RH) and somatostatin in the organum vasculosum of the lamina terminalis of the rat (1977) (17)
Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH (1992) (17)
Reversible Effects of Long‐Term Treatment with D‐Trp6‐LH‐RH‐Microcapsules on Pituitary‐Gonadal Axis, Spermatogenesis and Prostate Morphology in Adolescent and Adult Dogs (2009) (17)
Determination of CRF activity in rats treated with Monase, dexamethasone, and morphine. (1965) (17)
Suppression of the positive feedback of estradiol benzoate on gonadotropin secretion by an inhibitory analog of luteinizing hormone-releasing hormone (LRH) in oophorectomized rhesus monkeys: evidence for a necessary synergism between LRH and estrogens. (1983) (17)
Characterization of the Corticotrophin Releasing Factor of the Neurohypophysis (1958) (17)
Release of Luteinizing Hormone by Synthetic LH-Releasing Hormone in the Ewe and Ram 1 (1972) (17)
LH-RH analogue carrying a cytotoxic radical is internalized by rat pituitary cells in vitro (1994) (17)
Administration of LH-releasing hormone of human origin to man. (1971) (17)
Differential expression of GHRH receptor and its splice variant 1 in human normal and malignant mucosa of the oesophagus and colon. (2008) (17)
A tyrosine phosphatase is associated with the somatostatin receptor. (1995) (17)
Isolation and Chemical Characterization of a β-CRF from Pig Posterior Pituitary Glands.∗ (1963) (17)
Inhibitory effects of antagonists of growth hormone‐releasing hormone on growth and invasiveness of PC3 human prostate cancer (2013) (17)
In vivo fluorescence imaging and urinary monoamines as surrogate biomarkers of disease progression in a mouse model of pheochromocytoma. (2014) (17)
Protective effect of Growth Hormone-Releasing Hormone agonist in bacterial toxin-induced pulmonary barrier dysfunction (2014) (17)
Identity of Prolactin Inhibiting Factor (PIF) and Luteinizing Hormone-Releasing Factor (LRF).∗ (1964) (17)
Gene expression of vasoactive intestinal peptide receptors in human lung cancer. (2011) (17)
The effect of gastrointestinal hormones on the incorporation of tritiated thymidine in the pancreatic adenocarcinoma cell line (WD PaCa) (1989) (17)
Targeted chemotherapy with cytotoxic bombesin analogue AN‐215 can overcome chemoresistance in experimental renal cell carcinomas (2005) (17)
Receptors for luteinizing hormone‐releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix (2011) (17)
Danazol effects on gonadotropin basal levels and pituitary responsiveness to LH-RH in immature male rats. (1978) (17)
Growth Hormone-Releasing Hormone in Diabetes (2016) (17)
Somatostatin analogs in the treatment of various experimental tumors (1986) (16)
Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer. (1989) (16)
Structure-activity relationships in luteinizing hormone-releasing hormone. (1976) (16)
Prolonged elevation of luteinizing hormone (LH) after intranasal administration of an analog of LH-releasing hormone. (1976) (16)
Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238. (2002) (16)
Growth Hormone-Releasing Hormone Antagonists Inhibit Growth of Human Ovarian Cancer (2011) (16)
Suppression of meiosis of male germ cells by an antagonist of luteinizing hormone-releasing hormone. (1990) (16)
Inhibition of experimental U-118MG glioblastoma by targeted cytotoxic analogs of bombesin and somatostatin is associated with a suppression of angiogenic and antiapoptotic mechanisms. (2005) (16)
Characteristics of antibody produced during chronic treatment with LHRH. (1977) (16)
Effects of highly potent octapeptide analogs of somatostatin on growth hormone, insulin and glucagon release. (1987) (16)
Neuropeptide Influences on the Central Nervous System: A Psychobiological Perspective (1981) (16)
Passive and active avoidance responses at two levels of shock after administration of melanocyte-stimulating hormone (1972) (16)
Luteinizing hormone-releasing hormone analogs lacking N-terminal pGlu ring structure. (1973) (16)
Vasoactive intestinal peptide induces oxidative stress and suppresses metastatic potential in human clear cell renal cell carcinoma (2013) (16)
Lack of relationship between the levels of prolactin receptors and steroid receptors in women with breast cancer. (1988) (16)
Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone (2013) (16)
High potency of a new bombesin antagonist (RC-3095) in inhibiting serum gastrin levels; comparison of different routes of administration (1992) (16)
Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group. (1996) (16)
Powerful Inhibition of Experimental Human Pancreatic Cancers by Receptor Targeted Cytotoxic LH-RH analog AEZS-108 (2013) (16)
The hypothalamus and pituitary in health and disease (1972) (16)
Signaling mechanisms of growth hormone-releasing hormone receptor in LPS-induced acute ocular inflammation (2020) (16)
Isolation of α- and β-Melanocyte Stimulating Hormones (MSH) on a Preparative Scale.∗ (1960) (16)
SOME BIOLOGICAL AND CHEMICAL PROPERTIES OF A LYSINE- VASOPRESSIN DIMER. (1964) (16)
Treatment of experimental ovarian carcinoma with monthly injection of the agonist D-Trp-6-LH-RH: a preliminary report. (1988) (16)
Antagonists of bombesin/gastrin‐releasing peptide as adjuncts to agonists of luteinizing hormone–releasing hormone in the treatment of experimental prostate cancer (1993) (16)
Clinical evaluation in men of a substance with growth hormone-releasing activity. (1972) (16)
STIMULATORY AND INHIBITORY ANALOGS OF LH-RH (1981) (15)
The effects of morphine and other narcotics on thyroid function in mice. (1966) (15)
Gonadotropin and prolactin secretion in human pseudocyesis: effect of synthetic luteinizing hormone-releasing hormone (LH-RH) and thyrotropin releasing hormone (TRH) (1974) (15)
Gastrin-Releasing Peptide Receptor Antagonism Induces Protection from Lethal Sepsis: Involvement of Toll-like Receptor 4 Signaling (2012) (15)
Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model. (1986) (15)
Immunohistochemical detection of growth hormone-release inhibiting hormone (somatostatin) in the guinea-pig brain (1975) (15)
Clinical studies with d-TRP6-luteinizing hormone-releasing hormone in men with hypogonadotropic hypogonadism. (1978) (15)
Expression and possible implication of growth hormone-releasing hormone receptor splice variant 1 in endometriosis. (2009) (15)
Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162 (2009) (15)
Effect of GHRH and peptides from the vasoactive intestinal peptide family on cAMP production of human cancer cell lines in vitro. (1999) (15)
Effect of purified luteinizing hormone-releasing factor on plasma and pituitary LH levels in castrated, testosterone pretreated male and female rats. (1967) (15)
Increased potency of four analogues of LH-releasing hormone in man. (1974) (15)
GHRH Antagonists Protect Against Hydrogen Peroxide-Induced Breakdown of Brain Microvascular Endothelium Integrity (2020) (15)
Effect of Thyrotropin Releasing Hormone (TRH) on the Menstrual Cycle in Women (1974) (15)
Peptide analogues alter the progression of premalignant lesions, as measured by Photofrin fluorescence. (1993) (15)
Hypothalamic hormones: the link between brain and body. (1977) (15)
Mechanism of action of growth hormone in altering its own secretion rate: comparison with the action of dexamethasone. (1967) (15)
Pituitary responsiveness to synthetic luteinizing hormone-releasing hormone during pregnancy: effect on follicle-stimulating hormone secretion. (1973) (15)
In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses (2001) (15)
Studies on the properties of hypothalamic luteinizing hormone-releasing hormone. (1971) (15)
Effects of Hypophysectomy on Hypothalamic Obesity in CBA Mice.∗ (1966) (15)
Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors (1994) (15)
Anti-Luteinizing Hormone (LH)-Releasing Activity of Several Analogues of LH-Releasing Hormone (1975) (15)
A method for evaluation of activity of antagonistic analogs of growth hormone-releasing hormone in a superfusion system. (1993) (15)
Effect of TRH and Triiodothyronine on Prolactin Release in Sheep 1 (1973) (15)
Antagonistic analogs of growth hormone-releasing hormone increase the efficacy of treatment of triple negative breast cancer in nude mice with doxorubicin; A preclinical study (2014) (15)
Essential role of p21/waf1 in the mediation of the anti-proliferative effects of GHRH antagonist JMR-132. (2008) (15)
Differential immunostaining of various types of breast carcinomas for growth hormone‐releasing hormone receptor – Apocrine epithelium and carcinomas emerging as uniformly positive (2014) (15)
Blockade of the LH response induced by the agonist D‐Trp‐6‐LHRH in rats by a highly potent LH‐RH antagonist SB‐75 (1992) (15)
Lipid mobilizing hormones of the hypothalamus and pituitary. (1975) (15)
Growth inhibition of experimental non‐Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN‐238 (2005) (15)
Current concept for improving treatment of prostate cancer based on combination of LH-RH agonists with other agents. (1987) (14)
Attempts to programme ovulation with exogenous oestrogens and LH-RH analogue. (1975) (14)
ANALOGS OF LUTEINIZING HORMONE-RELEASING HORMONE WITH INCREASED BIOLOGICAL ACTIVITY PRODUCED BY D-AMINO ACID SUBSTITUTIONS IN POSITION 6 (1976) (14)
Luteinizing Hormone-Releasing Hormone (LHRH)-I Antagonist Cetrorelix Inhibits Myeloma Cell Growth In vitro and In vivo (2010) (14)
Persistent blockade of the pituitary‐gonadal axis in patients with prostatic carcinoma during chronic administration of D‐Trp‐6‐LH‐RH (1986) (14)
Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues : Mediation by human somatostatin receptor subtypes SSTR 1 and SSTR 2 ( somatostati analogue RC-160 / SMS-2015 / deased ce growh / cancer ) (14)
Modulation of the pancreatic islet-stress axis as a novel potential therapeutic target in diabetes mellitus. (2014) (14)
Inhibition of prolactin release in vitro and in vivo by catecholamines (1974) (14)
Antagonists of bombesin/gastrin-releasing peptide decrease the expression of angiogenic and anti-apoptotic factors in human glioblastoma (2005) (14)
Stimulation of growth hormone release by anterior pituitary perfusion in the rat. (1972) (14)
Disparity in the negative gonadal feedback control for LH and FSH secretion in cases of germinal aplasia or Sertoli-cell-only syndrome. (1974) (14)
Additional evidence for dissociation of melanocyte-stimulating hormone and corticotrophin release. (1972) (14)
Effects of growth hormone-releasing hormone and its agonistic and antagonistic analogs in cancer and non-cancerous cell lines. (2010) (14)
Inhibitory effects of the new bombesin receptor antagonist RC-3095 on the luteinizing hormone release in rats. (1992) (14)
Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist. (2008) (14)
Lack of luteolytic effect of D-Trp-6-LH-RH in hypophysectomized rhesus monkeys (Macaca mulatta). (1981) (14)
The hypothalamus and reproduction. (1975) (14)
Selective effect of some somatostatin analogs on glucagon as opposed to insulin release in rats in vivo. (1980) (14)
Dephosphorylation of cancer protein by tyrosine phosphatases in response to analogs of luteinizing hormone-releasing hormone and somatostatin. (2008) (14)
Targeting to Peptide Receptors (2011) (14)
Topical absorption of polypeptides with dimethylsulfoxide. (1966) (14)
Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models (2014) (14)
Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro (2013) (14)
Inhibition of the pituitary‐gonadal axis by a single intramuscular administration of D‐trp‐6‐LH‐RH (decapeptyl) in a sustained‐release formulation in patients with prostatic carcinoma (1989) (14)
Luteinizing hormone‐releasing hormone analogues and hormone ablation for prostate cancer: state of the art (2007) (14)
Suppression of LH-RH-induced ovulation in hamsters and rats by synthetic analogues of LH-RH. (1976) (14)
Is the postovulatory release of follicle-stimulating hormone in the rabbit mediated by luteinizing hormone-releasing hormone? (1983) (14)
Direct action of growth hormone-releasing hormone agonist JI-38 on normal human fibroblasts: Evidence from studies on cell proliferation and c-myc proto-oncogene expression (2001) (14)
Comment on the debate article: embryo implantation: the Rubicon for GnRH antagonists. (2001) (14)
The effects of chronic administration of LH-RH agonists and antagonists on the menstrual cycle and endometrium of the rhesus monkey. (1984) (14)
LH-RH-containing nerve fibers in the brain of rats treated with sulpiride or reserpine (1978) (14)
LHRH Agonists as Adjuncts to Somatostatin Analogs in the Treatment of Pancreatic Cancer (1990) (13)
Chronic administration of a new potent agonist of growth hormone- releasing hormone induces compensatory linear growth in growth hormone-deficient rats: mechanism of action. (1996) (13)
Synthesis and biological properties of (2-L-beta-(pyrazolyl-3)alanine)-luteinizing hormone-releasing hormone. (1974) (13)
Basic and clinical studies with luteinizing hormone-releasing hormone (LH-RH) and its analogues. (1973) (13)
In vivo release of follicle-stimulating hormone following administration of hypothalamic extracts in normal, castrated, and castrated testosterone-treated rats. (1967) (13)
Introduction of LHRH-antagonists into the treatment of gynaecological disorders. (1994) (13)
Inhibitory effect of somatostatin-28 on pancreatic polypeptide, glucagon and insulin secretion in normal man. (1983) (13)
Studies on the mechanism of action of a targeted chemotherapeutic drug in living cancer cells by two photon laser scanning microspectrofluorometry. (2001) (13)
Effects of Combined Long-Term Treatment with a Growth Hormone-Releasing Hormone Analogue and a Growth Hormone Secretagogue in the Growth Hormone-Releasing Hormone Knock Out Mouse (2006) (13)
Administration of luteinizing hormone-releasing hormone analogs delays ovulation without affecting the luteal function in rhesus monkeys. (1983) (13)
Involvement of neurotransmitters in the action of growth hormone-releasing hormone antagonist on passive avoidance learning (2012) (13)
Radioimmunoassay of CRF-Like Material in Rat Plasma: Validation of the Method (1983) (13)
Evaluation of the gonadotrophic responsiveness of the pituitary to acute and prolonged administration of LH/FSH-releasing hormone (LH-RH) in normal females and males. (1979) (13)
Neurotransmitter-mediated action of an antagonist of growth hormone-releasing hormone on anxiolysis in mice (2012) (13)
Possible predictors of histopathological response to neoadjuvant chemoradiotherapy for rectal cancer (2012) (13)
Responsiveness of pituitary hGH to GRH1-44 in juveniles with obesity. (1986) (13)
BASIC APPLICATIONS AND CLINICAL USES OF HYPOTHALAMIC HORMONES: experimental and clinical studies (1976) (13)
Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma (2013) (13)
Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination (1992) (13)
Synthesis and biological evaluation of 4-alanine-luteinizing hormone-releasing hormone ([Ala4] LH-RH) (1972) (13)
The Presence of Prolactin Inhibiting Factor (PIF) in Extracts of Beef, Sheep and Pig Hypothalami∗ (1965) (13)
Response to a growth hormone-releasing hormone analog in heifers treated with recombinant growth hormone. (1988) (13)
Stimulation of insulin secretion by corticotropin-releasing factor (CRF) in anesthetized rats (1984) (13)
Stereoisomers of luteinizing hormone-releasing hormone. (1974) (13)
Extracorporeal apheresis therapy for Alzheimer disease—targeting lipids, stress, and inflammation (2019) (13)
An evaluation of intravenous, subcutaneous, and in vitro activity of new agmatine analogs of growth hormone-releasing hormone hGH-RH (1-29)NH2. (1988) (13)
COMPARISON OF LONG‐ACTING ANALOGUES OF LUTEINIZING HORMONE RELEASING HORMONE IN MAN (1979) (13)
Luteinizing Hormone-Releasing Hormone in the Treatment of Anovulatory Infertility (1975) (13)
Rationally designed cyclic analogues of luteinizing hormone-releasing hormone: enhanced enzymatic stability and biological properties. (2012) (13)
The effect of D-Trp6-LRH upon secretion of gonadotrophin--a possible therapeutic application in anorexia nervosa. (1984) (13)
Hypothalamic releasing and inhibiting hormones (1972) (12)
Antiserum to LH-RH blocks haloperidol-induced hyperprolactinemia in female rats. (1985) (12)
Concentration of Corticotropin Releasing Factor by Chromatography on Carboxymethylcellulose (1959) (12)
Targeted Cytotoxic Analogue of Luteinizing Hormone‐Releasing Hormone (LH‐RH) Only Transiently Decreases the Gene Expression of Pituitary Receptors for LH‐RH (2002) (12)
In vivo depletion of pituitary growth hormone by hypothalamic extracts. (1965) (12)
Use of GnRH in preference to LH-RH terminology in scientific papers. (2000) (12)
Development of a radioimmunoassay for some agonists of growth hormone-releasing hormone. (2009) (12)
Fibrocystic disease of the breast in premenopausal women: histohormonal correlation and response to luteinizing hormone releasing hormone analog treatment. (1991) (12)
Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes (2016) (12)
Parellel inhibition of LH-RH-induced cyclic AMP accumulation and LH and FSH release by LH-RH antagonists in vitro. (1975) (12)
Lipid mobilizing factor from the hypothalamus. (1970) (12)
Purification of Growth Hormone-Releasing Factor from Beef Hypothalamus.∗ (1966) (12)
Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumour growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers. (2004) (12)
Structural investigation of Cetrorelix, a new potent and long-acting LH-RH antagonist. (2009) (12)
Increase in basal and thyrotropin release stimulated secretion of thyrotropin and the effect of triiodothyronine in rats passively immunized with antiserum to somatostatin (1976) (12)
Absence of prolactin-release inhibiting activity in highly purified LH-releasing factor. (1967) (12)
Growth hormone-releasing hormone (GHRH) and its agonists inhibit hepatic and tumoral secretion of IGF-1 (2018) (12)
Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma. (2005) (12)
Unaltered Plasma Prolactin Levels in Men After Administration of Synthetic LH-Releasing Hormone (1973) (12)
An in vivo model for testing inhibition of arginine-induced insulin and glucagon release by somatostatin analogs. (1977) (12)
Superactive somatostatin analog decreases plasma glucose and glucagon levels in diabetic rats (1988) (12)
Clinical comparison of natural LH-RH, synthetic LH-RH, and two analogues of LH-RH. (1974) (12)
Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone‐releasing hormone analog AN‐207 (2006) (12)
Purification and in vitro and in vivo studies with porcine hypothalamic follicle-stimulating hormone-releasing factor. (1967) (12)
Micromethod for the determination of free and total prolactin receptors: measurement of receptor levels in normal and malignant mammary and prostate tissues. (1986) (12)
Purification and characterization of peptides with corticotropin-releasing factor activity from porcine hypothalami. (1986) (12)
Pituitary secretory reserve in patients with amenorrhea associated with galactorrhea. (1974) (12)
Growth hormone-releasing activity in plasma of normal and hypophysectomized rats. (1967) (12)
Unusual dose-related effect of an endorphin analog in a complex maze (1980) (12)
Inhibition of release in the baboon by inhibitory analogs of lutheinizing hormone releasing hormone. (1977) (12)
The role of FSH and LH in prostate cancer and cardiometabolic comorbidities. (2020) (12)
Plasma Progestins in Anestrous Ewes Treated with D-Leu Des GlyNH -LHRH Ethylamide (1977) (12)
Effects of an LH-RH analogue in male rats pretreated with oestradiol benzoate. (1978) (12)
Effect of Thyroid Hormone Excess and Deficiency on Serum Thyrotropin in Rats Immunized Passively with Antiserum to Somatostatin 1 (1976) (12)
Combination treatment of nitrosamiee-induced pancreatic cancers in hamsters with analogs of LH-RH and a bombesin/GRP antagonist (1994) (11)
ANALOGUES OF GROWTH-HORMONE RELEASE-INHIBITING HORMONE (1975) (11)
Selective induction of apoptosis by the cytotoxic analog AN-207 in cells expressing recombinant receptor for luteinizing hormone-releasing hormone. (1999) (11)
Development of a method to test anti-LH-RH activity in rats. (1974) (11)
Structure-Activity Relationship of LH and FSH Releasing Hormone (1975) (11)
Recovery of pituitary-gonadal function in male rats after long-term suppression induced by a single injection of microcapsules of LH-RH antagonist cetrorelix (SB-75). (1993) (11)
The concentration of LH-RH receptors in the nuclei of pancreatic cancer cells. Effect of (D-Trp6)LH-RH on tumor-bearing Syrian golden hamsters. (1994) (11)
Stimulation of adenosine 3',5'-cyclic monophosphate accumulation in anterior pituitary gland in vitro by purified growth hormone-releasing hormone. (1973) (11)
Isolation, structure, biological characterization, and synthesis of beta-[Tyr9]melanotropin-(9-18) decapeptide from pig hypothalami. (1980) (11)
Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Thyroid Cancer (2017) (11)
Differential effects of LHRH and somatostatin analogs on human breast cancer. (1992) (11)
Effect of porcine growth hormone-releasing factor on the release and synthesis of growth hormone in vitro. (1968) (11)
Growth hormone‐releasing hormone receptor mediates cytokine production in ciliary and iris epithelial cells during LPS‐induced ocular inflammation (2019) (11)
In Vivo Comparison of LH-RH and FSH-RH Activities of [DES-GLY10] [PRO9-Ethylamide]-LH-RH, [DES-GLY10][PRO9-Propylamide]-LH-RH, and LH-RH Using Immature Male Rats 1 (1974) (11)
Growth Hormone-Releasing Activity in the Hypothalamus and Plasma of Rats Subjected to Stress.∗ (1967) (11)
Different effect of potassium and calcium ion on the release of growth hormone and prolactin from isolated rat pituitaries in vitro. (1972) (11)
Inhibition of serum luteinizing hormone and testosterone with an inhibitory analog of luteinizing hormone-releasing hormone in adult male rhesus monkeys. (1984) (11)
Presence of Thyrotropic Hormone-Releasing Factor (TRF) In Porcine Hypothalamus.∗ (1966) (11)
GH, but not GHRH, plays a role in the development of experimental autoimmune encephalomyelitis. (2011) (11)
Effect of CNS-depressants, dexamethasone and growth hormone on the response to growth hormone-releasing factor. (1967) (11)
Inhibitory effects of antagonistic analogs of GHRH on GH3 pituitary cells overexpressing the human GHRH receptor. (2002) (11)
Pituitary response to synthetic luteinizing hormone-releasing hormone in Prader-Willi syndrome, prepubertal and pubertal children. (1974) (11)
Effects of a long-acting LHRH agonist preparation on plasma gonadotropin and prolactin levels in castrated male rats and on the release of prolactin from ectopic pituitaries (1986) (11)
Comparison of biological effects of a sustained delivery system and nonencapsulated LH-RH antagonist SB-75 in rats (1992) (11)
Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone. (2008) (11)
Evaluation of the in vitro and in vivo activity of the L-, D,L- and D-Cit6 forms of the LH-RH antagonist Cetrorelix (SB-75). (2009) (11)
Potentiating effects of GHRH analogs on the response to chemotherapy (2015) (11)
Selective uptake of the somatostatin analog RC‐160 across the blood‐brain tumor barrier of mice with KHT sarcomas (1992) (10)
Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cells (2013) (10)
Protective effects of growth hormone-releasing hormone analogs in DSS-induced colitis in mice (2021) (10)
Use of luteinizing hormone-releasing hormone analogs in the treatment of hormone-dependent tumors (1987) (10)
Immunocytochemical demonstration of tissue transglutaminase indicative of programmed cell death (apoptosis) in hormone sensitive mammary tumours. (1991) (10)
Characterization of the LH response to luteinizing hormone-releasing hormone (LH-RH) in isolated and multiple tropic hormone deficiencies. (1973) (10)
Effect of long-acting antagonists of growth hormone (GH)-releasing hormone on GH and cyclic adenosine 3',5'-monophosphate release in superfused rat pituitary cells. (1995) (10)
Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction (2021) (10)
Effects of intracerebroventricular administration of ovine corticotropin-releasing factor (CRF 1–41) on passive avoidance behaviour: Lack of influence on monoamine contents of limbic brain areas (1985) (10)
Potent agonists of growth hormone-releasing hormone. Part I. (2009) (10)
Synthesis and in vitro and in vivo activity of analogs of growth hormone-releasing hormone (GH-RH) with C-terminal agmatine. (2009) (10)
Proceedings: Inhibition of gastrin and gastric acid by growth hormone release inhibiting hormone. (1975) (10)
Current status of antagonistic analogs of LH-RH as a contraceptive method in the female. (1983) (10)
Potentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonists (2013) (10)
Delayed release formulation of the somatostatin analog RC-160 inhibits the growth hormone (GH) response to GH-releasing factor-(1-29)NH2 and decreases elevated prolactin levels in rats. (1988) (10)
1 – Hypothalamic Peptide Hormones: Basic and Clinical Studies (1979) (10)
Depletion of pituitary follicle-stimulating hormone by beef and pig hypothalamic extracts. (1966) (10)
Effects of dexamethasone and pentobarbital on plasma growth hormone levels in rats. (1971) (10)
Studies on the enzymatic and chemical inactivation of hypothalamic follicle-stimulating hormone-releasing hormone. (1971) (10)
INHIBITORY ACTIVITY OF ANALOGUES OF LUTEINIZING HORMONE‐RELEASING HORMONE (LH‐RH) IN VITRO AND IN VIVO (1976) (10)
On the tryptophan residue in porcine LH and FSH-releasing hormone. (1971) (10)
Synthesis and biological activity of position 1 analogs of LH-RH. (2009) (10)
Neuropharmacological actions of the superactive agonist analog D-Trp-6-LH-RH after peripheral injection into mice (1990) (10)
Follicle-stimulating hormone-releasing activity in peripheral blood. (1967) (10)
LH-RH antagonists: Further analogs with ring-substituted aromatic residues (1981) (10)
Hypothalamic regulation of FSH and LH secretion. (1970) (10)
Bombesin antagonist prevents CO2 laser-induced promotion of oral cancer. (1996) (10)
CNS and pituitary effects of hypothalamic peptides and MSH. (1977) (9)
Terminology for luteinizing hormone-releasing hormone antagonists. (1995) (9)
Suppression of gonadotropin release and ovulation in animals by inhibitory analogs of luteinizing hormone-releasing hormone. (1976) (9)
Prolonged anti-luteinizing hormone/follicle-stimulating hormone-releasing activities of some synthetic antagonists of luteinizing hormone-releasing hormone. (1976) (9)
Assessment of GH releasing hormone activity in sephadex-separated fractions of porcine hypothalamic extracts by hypophyseal portal vessel infusion in the rat. (1975) (9)
Expression of progenitor markers is associated with the functionality of a bioartificial adrenal cortex (2018) (9)
Inhibition of growth of a prolactin and growth hormone-secreting pituitary tumor in rats by D-tryptophan-6 analog of luteinizing hormone-releasing hormone. (1985) (9)
Clinical studies with d-Trp 6-luteinizing hormone-releasing hormone in anovulatory women. (1978) (9)
Inhibition of the release of growth hormone in vitro by -melanocyte stimulating hormone. (1973) (9)
Chapter 1 – Physiology and Nature of Hypothalamic Regulatory Hormones (1977) (9)
Isolation and characterization of two peptides with prolactin release-inhibiting activity from porcine hypothalami. (1991) (9)
Inhibition by pig hypothalamic extracts of depletion of pituitary prolactin in rats following cervical stimulation. (1966) (9)
The Effect of LHRH Antagonist Cetrorelix in Crossover Conditioned Media from Epithelial (BPH-1) and Stromal (WPMY-1) Prostate Cells (2013) (9)
D-leucine-6-luteinizing hormone-releasing hormone ethylamide in the treatment of normogonadotropic oligoasthenospermia. (1978) (9)
Growth hormone‐releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer (2018) (9)
Inhibition of Human Epithelial Ovarian Cancer Cell Growth in vitro by Somatostatin Analog RC-160 (2000) (9)
Correlation between in vivo inhibition of gonadotropin release induced by LH-RH and the blockade of ovulation by synthetic analogues of LH-RH. (1978) (9)
Effect of a powerful antagonist of LH-RH on testicular function in prepubertal male rats. (1983) (9)
A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormone‐releasing hormone (2018) (9)
Studies of a controlled-release microcapsule formulation of an LH-RH agonist (D-Trp-6-LH-RH) in the rhesus monkey menstrual cycle. (1985) (9)
Effect of Estradiol on the Response to LH-RH in Male Rats at Different Times After Castration 1 (1973) (9)
Melanocyte-stimulating Hormone Activity of Synthetic MSH and ACTH Peptides, in vivo and in vitro (1965) (9)
Stimulation of release of FSH and LH by infusion of LH-RH and some of its analogues. (1973) (9)
Isolation, structure and synthesis of a heptapeptide with in vitro ACTH-releasing activity from porcine hypothalamus. (1981) (9)
The Immunohistochemical Expression of Growth Hormone-Releasing Hormone Receptor Splice Variant 1 Is a Favorable Prognostic Marker in Colorectal Cancer (2009) (9)
Antagonistic activity of analogs of luteinizing hormone-releasing hormone (LH-RH) in vitro (1976) (9)
Inhibition of cell growth by a hypothalamic peptide. (1982) (9)
Influence of LH-RH agonists and antagonists on gonadotropin release in humans. (1980) (9)
Response of luteinizing hormone and follicle-stimulating hormone to different doses of D-leucine-6-LH-RH ethylamide in oligospermic patients. (1976) (9)
MSH-release inhibiting factors: recent studies. (1973) (8)
Effects of new bombesin antagonists given singly or in combination with a somatostatin analog on nitrosamine-induced pancreatic cancers in hamsters. (1996) (8)
Induction of Apoptosis in Pterygium Cells by Antagonists of Growth Hormone-Releasing Hormone Receptors. (2018) (8)
Endocrine and Extra-Endocrine Studies of Hypothalamic Hormones in Man (1974) (8)
Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells (2016) (8)
The effect of surgical isolation of the hypothalamus on its luteinizing hormone-releasing hormone content. (1976) (8)
The actions of luteinizing hormone-releasing hormone agonists, antagonists, and cytotoxic analogues on the luteinizing hormone-releasing hormone receptors on the pituitary and tumors (2001) (8)
The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma (2020) (8)
Pituitary and testicular response to hypothalamic LH-releasing hormone (LH-RH) in normal and oligospermic men. (1976) (8)
Ontogenesis of the LH-RH-containing neuronal elements in the hypothalamus of the rat. (1978) (8)
Stimulatory and inhibitory analogs of luteinizing hormone releasing hormone (LHRH). (1977) (8)
Some questions related to melanocyte-stimulating hormone. (1976) (8)
Different responses to two hypothalamic hormones in acromegalics. (1972) (8)
Synthesis of luteinizing hormone-releasing hormone containing tritium-labelled pyroglutamic acid. (1973) (8)
Endocrine effects of new bombesin/gastrin-releasing peptide antagonists in rats. (1992) (8)
Chromatographic separation of oxytocin and vasopressin on carboxymethylcellulose. (1959) (8)
Effects of β-/Tyr9/melanotropin-/9–18/ decapeptide on catecholamine disappearance and serotonin accumulation in discrete brain regions of rats (1981) (8)
MALE CONTRACEPTION INVOLVING TESTOSTERONE SUPPLEMENTATION: POSSIBLE INCREASED RISKS OF PROSTATE CANCER? (1987) (8)
Growth Hormone-Releasing Hormone in Lung Physiology and Pulmonary Disease (2020) (8)
Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin (1989) (8)
Melanocyte-stimulating hormone and learned appetitive behavior (1969) (8)
Response to LH-RH in women before and after treatment with prednisone. (1974) (8)
Inhibition of Sham Feeding-Induced Gastric Secretion and Serum Hormonal Responses by Analogs of (pyro)Glu-His-Gly-OH (1982) (8)
Evaluation of in vitro biological activity of new agmatine analogs of growth hormone-releasing hormone (GH-RH) (1990) (8)
Effect of somatostatin analogs on gastric acid secretion in dogs and rats. (2009) (8)
Structural Motif Descriptors as a Way To Elucidate the Agonistic or Antagonistic Activity of Growth Hormone–Releasing Hormone Peptide Analogues (2018) (8)
Induction of Ovulation with Synthetic Gonadotrophin-Releasing Hormone in Women with Constant Anovulation Induced by Contraceptive Steroids (1974) (8)
Some notes on the background of the isolation, determination of structure, synthesis, and early clinical trials of the luteinizing hormone- and follicle-stimulating hormone-releasing hormone. (1976) (7)
Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi) (2021) (7)
The interaction between β-[Tyr9]melanotropin-(9–18), haloperidol and amphetamine in different behavior tests of rats (1982) (7)
Plasma MSH and cortisol levels in 567 patients with special reference to brain trauma. (1974) (7)
Prolactin-lowering effect of luteinizing hormone-releasing hormone agonist administration in prolactinoma patients. (1989) (7)
Targeted cytotoxic analogs of luteinizing hormone-releasing hormone: a reply. (2001) (7)
MSH activity in the rat pituitary after treatment with Nembutal and morphine: a new bioassay for MSH-release inhibiting factor (MIF). (1968) (7)
Blockade of the Pre-ovulatory LH Surge in Hamsters by an Inhibitory Analog of LH-RH 1 (1975) (7)
New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones (2015) (7)
Prolactin release inhibiting and stimulating factors in the hypothalamus. (1977) (7)
Prolonged Release of LH and FSH and Depletion of Pituitary Gonadotropin Content after Administration of [d-LEU6, desGly-NH2 10]-LH-RH Ethylamide 1 (1977) (7)
Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer (2016) (7)
Pituitary FSH and LH reserve in women with isolated gonadotropin deficiency. (1973) (7)
Effect of D-leucine-6-luteinizing hormone-releasing hormone ethylamide in patients with hypogonadotropic hypogonadism with anosmia. (1979) (7)
Expression of hypothalamic neurohormones and their receptors in the human eye. (2017) (7)
A simple twenty-four hour test to evaluate hypothalamus-pituitary-adrenal cortical function. (1968) (7)
Effects of an Antagonistic Analog of Growth Hormone-Releasing Hormone on Endometriosis in a Mouse Model and In Vitro (2017) (7)
Dynamics of injected somatostatin in blood of patients with hepatic failure and acromegaly (1980) (7)
An inhibitor of urokinase and tissue plasminogen activators in Dunning R3327H prostate tumors of rats treated with D-Trp6-LH-RH. (1985) (7)
Antitumor effects of analogs of somatostatin and antagonists of bombesin/GRP in experimental models of pancreatic cancer (1994) (7)
Inhibitory activity of four analogs of luteinizing hormone-releasing hormone in vivo. (1975) (7)
Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II (2012) (7)
Treatment of Hormone‐Dependent Cancer with Analogues of Hypothalamic Hormones. Experimental and Clinical Studies a (1987) (7)
Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor (1992) (7)
Growth hormone-releasing hormone antagonist inhibits the invasiveness of human endometrial cancer cells by down-regulating twist and N-cadherin expression (2016) (7)
Bombesin induces a reduction of somatostatin inhibition of adenylyl cyclase activity, Gi function, and somatostatin receptors in rat exocrine pancreas (1999) (7)
New analogs of human growth hormone-releasing hormone (1-29) with high and prolonged antagonistic activity. (2009) (7)
Reduced postpartum anestrus of suckled beef cows treated with microencapsulated luteinizing hormone-releasing hormone analog. (1992) (7)
Delayed disappearance of 14C-labeled-pro-leu gly-HN2, from the blood of hypophysectomized rats. (1974) (7)
MSH activity in plasma and pituitaries of rats with large hypothalamic lesions. (1973) (7)
EFFECTS OF AGE, SEX, CASTRATION AND THE ADMINISTRATION OF TESTOSTERONE AND ESTRADIOL ON LEVELS OF SERUM CHOLESTERYL ESTER FATTY ACIDS IN RATS. (1965) (7)
Influence of Estradiol Benzoate on Pituitary Responsiveness to LH-RH at Different Stages of the Estrous Cycle in Rats 1 (1974) (7)
Studies on the iodination of LH-RH and the biological and immunological activities of the products. (1980) (7)
LHRH and Steroid Levels in Normal Ovulatory Women (1976) (7)
Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists (2019) (7)
Isolation of gram amounts of arginine vasopressin, oxytocin, and α-MSH (1964) (6)
Observations on the growth hormone, insulin, and glucagon release-inhibiting activities of somatostatin analogues. (1978) (6)
Expression of mRNA for human type-I LHRH receptor transcript forms in human benign prostatic hyperplasia. (2009) (6)
EFFECT OF LYSINE VASOPRESSIN DIMERS ON BLOOD PRESSURE AND SOME ENDOCRINE FUNCTIONS. (1964) (6)
Countercurrent distribution as a tool for purification of hypothalamic hormones on a preparative scale. (1971) (6)
Partial reversal of behavioral action of the agonist D-Trp-6-LH-RH by naloxone in mice. (1990) (6)
Thyroid stimulating and pigmentary effects of synthetic peptides related to α-MSH and ACTH☆ (1967) (6)
Lack of prolactin release-inhibiting activity in synthetic LH-releasing hormone. (1972) (6)
Luteinizing hormone concentrations in serum of postpartum beef cows injected with microencapsulated luteinizing hormone-releasing hormone analog. (1989) (6)
The present concept of the nature of hypothalamic hormones stimulating and inhibiting the release of pituitary hormones. (1969) (6)
Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes (2014) (6)
Site of inactivation of melanocyte-stimulating hormone-release-inhibiting hormone by human plasma. (1973) (6)
CLEARANCE OF LUNG METASTASES OF PROSTATE CARCINOMA AFTER TREATMENT WITH LH-RH AGONIST (1984) (6)
D-Tryptophan-6-luteinizing hormone-releasing hormone in the treatment of normogonadotropic oligoasthenozoospermia (1982) (6)
Hypothalamic Hormones Regulating Pituitary (and Other) Functions: Their Physiology and Biochemistry as Well as Recent Studies with Their Synthetic Analogues (1979) (6)
Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: low induction of multidrug resistance proteins. (2005) (6)
Reciprocal changes in prolactin and growth hormone secretion in vitro after in vivo estrogen treatment. (1994) (6)
Inhibitory Effects of GHRH Antagonists on Human GH-Secreting Adenoma Tissue (2012) (6)
Effect of long-term administration of an analog of growth hormone-releasing factor on the GH response in rats. (1987) (6)
Distribution of 3H-alpha-MSH in rat brain. (1976) (6)
Endocrine approaches to treatment of Alzheimer's disease and other neurological conditions Part I: Some recollections of my association with Dr. Abba Kastin: A tale of successful collaboration (2015) (6)
Targeting of cytotoxic bombesin analog AN-215 to H-69 small cell lung carcinoma as demonstrated by semi-quantitative microsatellite analysis in vitro (1999) (6)
Lack of growth hormone-releasing activity of (pyro)Glu-Ser-Gly-NH2. (1973) (6)
CORTICOTROPIN‐RELEASING FACTOR: ISOLATION AND CHEMICAL PROPERTIES * (1977) (6)
Melanocyte-stimulating activity in serum and the aqueous flare response in rabbits. (1970) (6)
Possible Predictive Markers of Response to Therapy in Esophageal Squamous Cell Cancer (2017) (6)
The simultaneous determination of both the quantity and the fatty acid composition of the triglycerides in three to ten microliters of plasma (1966) (6)
Growth Hormone-Releasing Hormone Receptor Splice Variant 1 is Frequently Expressed in Oral Squamous Cell Carcinomas (2012) (6)
Hepatic lesions in Syrian golden hamsters with pancreatic carcinoma induced by N-nitrosobis(2-oxopropyl)amine (BOP). (1990) (6)
Quantitation of somatostatin inhibition of insulin-stimulated gastric acid and pepsin secretion in the cat. (1978) (6)
Concurrence of chromosome 3 and 4 aberrations in human uveal melanoma (2017) (6)
Inhibition of two-step urinary bladder carcinogenesis by the somatostatin analogue RC-160 (1992) (6)
Agonistic analog of growth hormone–releasing hormone promotes neurofunctional recovery and neural regeneration in ischemic stroke (2021) (6)
Effects of analogs of (pyro)Glu-His-Gly-OH on food consumption and gastric acid secretion in rats. (1984) (6)
Chromatography of steroids produced by rat adrenals in vitro. (1955) (6)
Pituitary Response to Luteinizing Hormone- Releasing Hormone Analog at Sea Level and High Altitudes (1982) (6)
Inhibitory effect of a highly potent antagonist of LH releasing hormone (SB-75) on the pituitary gonadal axis in the intact and castrated rat. (1993) (6)
The privileges of a Nobel laureate. (1995) (6)
The effect of β-(Tyr9)melanotropin-(9–18) on active avoidance behavior, electroconvulsive shock-induced amnesia and T-discrimination learning of rats (1986) (6)
Administration of agonistic and antagonistic analogues of LH-RH induce anovulation in Macaca fasicularis. (1983) (6)
Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogendependent MXT mouse mammary cancers: Correlations between growth characteristics and EGF receptor content of tumors (2005) (6)
Hypothalamic LH-Releasing Hormone: Chemistry, Physiology and Effect in Humans (1970) (5)
Synthesis and degradation of cyclic nucleotides in the pituitary gland, ovary and testis of rats treated with D-Trp6-luteinizing hormone-releasing hormone. (1981) (5)
Gonadotropin release during repeated administration of d-Leu6 des Gly10-LH-RH-EA at different stages of the menstrual cycle and in functional amenorrhea. (1980) (5)
Effects of danazol on gonadotropin secretion after ovariectomy in rats. (1978) (5)
Lh-rh and its antagonist cetrorelix inhibit growth of jar human choriocarcinoma cells in-vitro. (1995) (5)
Actions of novel bombesin receptor antagonists on pancreatic secretion in rats. (1992) (5)
Levels of luteinizing hormone (LH), follicle-stimulating hormone, and 17 beta-estradiol in response to D-Trp6-LH-releasing hormone during different phases of the menstrual cycle in normal women. (1978) (5)
Publisher Correction: Antinflammatory, antioxidant, and behavioral effects induced by administration of growth hormone-releasing hormone analogs in mice (2020) (5)
Increase in Plasma Growth Hormone (GH)-Like Activity After Administration of Porcine GH-Releasing Hormone 1 (1971) (5)
Growth hormone-releasing activity in the hypothalami of kittens with lesions of the region of the paraventricular nuclei. (1968) (5)
Administration of LH-releasing hormone to selected subjects (1971) (5)
D-Trp6-luteinizing hormone-releasing hormone inhibits sulpiride-induced hyperprolactinemia in normal men. (1987) (5)
Characterization of luteinizing hormone-releasing hormone receptor type I (LH-RH-I) as a potential molecular target in OCM-1 and OCM-3 human uveal melanoma cell lines (2018) (5)
Correlation of serum prolactin and LH response to stimulation with LH-RH before and after extirpation of pituitary adenomas with clinical outcome. (1977) (5)
The effect of porcine thyrotropin (TSH)-releasing hormone (TRH) on the release of TSH from sheep and goat anterior pituitary tissue in vitro. (1970) (5)
Mode of Action of LHRH Analogs (2003) (5)
Depletion of pituitary thyrotropic hormone by thyrotropin releasing factor. (1967) (5)
Effect of Lh-Rh on antibody formation, sperm count and plasma levels of gonadotropins and testosterone in normal men. (1974) (5)
Influence of previous cooling of rat pituitaries on the release of GH, LH and prolactin in vitro. (1973) (5)
Systematic delivery of the luteinizing hormone-releasing hormone (LH-RH) antagonist cetrorelix (SB-75) via pulmonary instillation in the unanesthetized awake sheep (1994) (5)
Synthesis and biological activity of LH-RH analogs modified at the carboxyl terminus. (1975) (5)
Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on the function of rat pituitary cells: tests in a long term superfusion system. (1993) (5)
Some recollections of early clinical studies on hypothalamic hormones: A tale of a successful international collaboration (2001) (5)
Inhibitory Effects of Somatostatin Analogs on Prolactin Secretion in Rats Pretreated with Estrogen or Haloperidol (1987) (5)
Inhibition of the growth of some hormone dependent tumors byd-Trp6-LH-RH (1984) (5)
Sites of paradoxical action of the LHRH agonist (D-Trp6)-LHRH. (1980) (5)
Effect of lysine vasopressin dimer on corticotropin release in man. (1968) (5)
Physiological and clinical studies with natural and synthetic luteinizing hormone-releasing hormone (LH-RH). (1972) (5)
Effects of H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH on passive and active avoidance behavior and on open-field activity of rats (1982) (5)
GHRH and wound healing (2011) (5)
The use of a potent stimulatory LHRH analog (D-Trp-6, LHRH) in the induction of ovulation. (1980) (5)
GROWTH HORMONE‐RELEASING FACTOR (GRF): PHYSIOLOGICAL AND BIOCHEMICAL STUDIES WITH GRF PREPARATIONS OF BOVINE AND PORCINE ORIGIN * (1968) (5)
Isolation and structure of hypothalamic MSH release-inhibition hormone. (1971) (5)
ON THE CONFIGURATION OF A LYSINE -VASOPRESSIN DIMER. (1965) (5)
Anovulatory uterine bleeding after administration of MSH to women with secondary amenorrhoea. (1972) (5)
Effects of β-/Tyr9/melanotropin-/9–18/ on apomorphine-induced stereotyped cage-climbing and on striatal dopamine release in mice. Comparative studies with amphetamine (1982) (5)
Somatostatin, basic and clinical studies. A review. (1980) (5)
An oriented phase-II trial ofd-Trp6-LH-RH in patients with prostatic carcinoma (1984) (5)
Therapeutic use of gonadoliberin (follicle-stimulating hormone/luteinizing hormone-releasing hormone) in women. (1976) (5)
Temporal changes in FSH and LH concentrations following the administration of a potent LH-RH inhibitory analogue ( [N-Ac-D-Trp1, 3, D-p-Cl-Phe2, D-Phe6, D-Ala10]-LH-RH) to oophorectomized rhesus monkeys. (1983) (5)
Composition of Plasma Triglyceride Fatty Acids and Free Fatty Acids in Hypothalamic Obese Mice.∗ (1967) (5)
Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma (2005) (5)
Protection of neonatal rat cardiac myocytes against radiation-induced damage with agonists of growth hormone-releasing hormone. (2016) (5)
Rat brain melanin at different ages and after various treatments (1979) (5)
Antagonists of growth hormone releasing hormone (GHRH) given before whole body radiation lead to modulation of radiation response and organ-specific changes in the expression of angiogenesis (2012) (5)
The mechanism whereby growth hormone-release inhibiting hormone (somatostatin) inhibits food stimulated gastric acid secretion in the cat (1975) (5)
Inhibition of gastric acid secretion by stereoisomers of somatostatin. (1978) (5)
Attempts to induce ovulation in amenorrheic patients using D-Ala-6-LH-RH propylamide. (1979) (4)
Use of the mouse vas deferens assay to evaluate the action of somatostatin peptides on gastric acid secretion. (1981) (4)
Discrimination between growth hormone (GH) deficiency of hypothalamic or pituitary origin: an aid in selecting patients for GH-releasing hormone (RH) prolonged therapy. (1988) (4)
Comparison of GH-stimulation by GH-RH(1-29)NH2 and an agmatine29 GH-RH analog, after intravenous, subcutaneous and intranasal administration and after pulmonary inhalation in rats. (2009) (4)
The effects of β-(TYR9)melanotropin-(9–18) and H-PHE-ILE-TYR-HIS-SER-TYR-LYS-OH on the analgesic action of morphine (1983) (4)
Pituitary and Plasma Growth Hormone-Like Activity after Administration of Highly Purified Pig Growth Hormone-Releasing Factor∗ (1968) (4)
EFFECTS OF ALPHA-AND BETA-MELANOCYTE STIMULATING HORMONES AND OTHER PEPTIDES ON THE THYROID IN MICE. (1964) (4)
Physiological, veterinary and clinical effects of hypothalamic releasing hormones (RH), especially LH-RH (1974) (4)
Luteinizing hormone (LH), follicle-stimulating hormone, and testosterone responses to consecutive injections of D-leucine-6-LH-releasing hormone ethylamide in normal men. (1977) (4)
Expression of Receptors for Pituitary-Type Growth Hormone-Releasing Hormone (pGHRH-R) in Human Papillary Thyroid Cancer Cells: Effects of GHRH Antagonists on Matrix Metalloproteinase-2 (2015) (4)
Improvement of cardiac and systemic function in old mice by agonist of growth hormone‐releasing hormone (2021) (4)
Evidence for the existence of two corticotrophin-releasing factors, alpha and beta. (1960) (4)
Proceedings: Investigation and treatment of a recurrent vipoma. (1975) (4)
In vivo studies on the mechanism of action of 6-dehydro-16-methylene-hydrocortisone (STC 407) on the hypothalamo-pituitary-adrenal axis in rats. (1970) (4)
Chapter 73 – LHRH Analogs (2013) (4)
Adrenocorticotrophic Activity of Melanophore-expanding Hormone Preparations from Beef Pituitary Glands (1954) (4)
The origin and ultrastructural characteristics of corticotropin-releasing factor (CRF)-immunoreactive nerve fibers in the posterior pituitary of the rat (1985) (4)
Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone‐releasing hormone analog (AN‐152) (2018) (4)
Long-acting agonists of LH-RH in the treatment of large ovarian endometriomas. (1987) (4)
Histological findings in the rat prostate cancer model during treatment with a luteinizing hormone‐releasing hormone agonist and novantrone (1987) (4)
Suppression of luteinization in the baboon by thyrotrophin-releasing hormone (TRH). (1977) (4)
Synthesis, purification and biological evaluation of porcine corticotropin-releasing factor. (1987) (4)
Use of analogs of LH-RH and somatostatin for the treatment of hormone dependent cancers. (1988) (4)
Search for novel therapies for triple negative breast cancers (TNBC): analogs of luteinizing hormone-releasing hormone (LHRH) and growth hormone-releasing hormone (GHRH) (2012) (4)
Development of a radioimmunoassay for a pseudononapeptide bombesin/GRP antagonist with antitumor activity. (2009) (4)
Effect of an antagonistic analog of LH-RH on haloperidol-induced hyperprolactinemia in female rats (1985) (4)
Effect of intracerebroventricular administration of β-/Tyr9/-melanotropin-/9–18/ on rotational behavior induced by substantia nigra lesion in rats (1983) (4)
Antagonists of Growth Hormone-releasing Hormone in Oncology (2006) (4)
Effect of chronic administration of a new potent agonist of GH-RH(1–29)NH2 on linear growth and GH responsiveness in rats (1996) (4)
Characterization of prolactin receptors and their distribution among American and Israeli women with breast cancer: implications for prediction of hormonal dependency and treatment. (1988) (4)
TRAITEMENT DES CANCERS PROSTATIQUES PAR ADMINISTRATION PERIODIQUE D'UNE PREPARATION A LIBERATION PROGRAMMEE DE D-Trp6-LH-RH (1986) (4)
ADVERSE EFFECT OF TAMOXIFEN WITH LHRH AGONIST ON OESTROGEN-RECEPTOR-NEGATIVE MAMMARY CARCINOMA (1989) (4)
191 PLASMA LEVELS OF D-TRP-6-LH-RH (DECAPEPTYL) AFTER INTRAMUSCULAR INJECTION OF LONG-ACTING MICROCAPSULES IN CHILDREN TREATED FOR PRECOCIOUS PUBERTY (PP) (1985) (4)
Comparison of the inhibition of histamine-and pentagastrin-stimulated gastric acid secretion by somatostatin in the cat (1977) (4)
Paradoxical effects of D-Trp6-LHRH in immature female rats correlated with changes in ACTH, prolactin, and corticosterone levels. (1981) (3)
In the Pursuit of Hypothalamic Hormones (1978) (3)
[Receptors for luteinizing hormone releasing hormone expressed on melanoma, renal cell carcinoma and non Hodgkin lymphoma can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues]. (2006) (3)
Localization of LH-RH-containing Neurons in the Rabbit Brain (1978) (3)
High gonadotropin releasing activity of two super active and long lasting analogues of luteinizing hormone releasing hormone after subcutaneous, oral, and vaginal administration (1975) (3)
Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity (2021) (3)
Treatment of Prostatic Carcinoma with D-Trp-6-LH-RH: Plasma Hormone Levels After Daily Subcutaneous Injections and Periodic Administration of Delayed-Release Preparations (1986) (3)
Luteotrophic and luteolytic effects of prolactin in hypophysectomized rats. (1970) (3)
Corticotropin-releasing factor (CRF)-immunoreactive neurons in the mammillary body of the rat (1985) (3)
Expression of hypothalamic neurohormones and their receptors in the human eye (2017) (3)
HETEROGENEITY OF HUMAN GROWTH HORMONE IN PLASMA AND URINE: INFLUENCE OF GROWTH HORMONE RELEASE INHIBITING HORMONE (1975) (3)
Growth hormone-releasing hormone receptor antagonist MIA-602 modulates mouse lung inflammation and fibrosis due to bleomycin (2018) (3)
LHRH receptor expression in sarcomas of bone and soft tissue (2016) (3)
La découverte des hormones hypothalamiques et le développement des analogues antitumoraux (2005) (3)
Absence of binding of targeted analogs of somatostatin carrying cytotoxic radicals or radionuclides to growth hormone secretagogue receptors on human myocardium. (2003) (3)
Classic pages in obstetrics and gynecology. Structure of the porcine LH-and FSH-releasing hormone. I. The proposed amino acid sequence. Biochemical and Biophysical Research Communications, vol. 43, pp. 1334-1339, 1971. (1976) (3)
Long-acting luteinizing homone-releasing hormone (LH-RH) analogs in the treatment of female infertility. (1976) (3)
Experimental protection by a luteinizing hormone-releasing hormone agonist of a bone marrow nitrosourea aplasia. Preliminary observations. (1984) (3)
On the nature of the hypothalamic substance which controls the secretion of ACTH (1961) (3)
Evidence for Separate Corticotrophin- and Luteinizing Hormone-Releasing Factors in Hypothalamic Extracts (1964) (3)
Synthesis and biological activity of a cyclic pseudohexapeptide analog of somatostatin. (1984) (3)
Induction of ovulation with D-Trp6-LHRH combined with purified FSH in patients with polycystic ovarian disease. (1988) (3)
Evaluation of biological activities of new LH-RH antagonists (T-series) in male and female rats. (2009) (3)
Independently of Their p 53 Status Somatostatin Receptor-positive Experimental Colon Cancers Targeted Cytotoxic Somatostatin Analogue AN-238 Inhibits Updated (2002) (3)
Effects of in vivo pretreatment with D-Trp-6-LH-RH on prolactin and LH secretion by pituitary glands in vitro (1985) (3)
[Effect of luteoliberin]. (1983) (3)
Preclinical therapy of benign prostatic hyperplasia with neuropeptide hormone antagonists (2014) (3)
Production of antiserum to LH releasing hormone (LH RH) and development of radioimmunoassay for LH RH (1973) (3)
Purification and characterisation of two porcine hypothalamic fractions with LH-releasing activity: evidence for a single LH and FSH-releasing hormone. (1975) (3)
Transactivation of HER 2 by vasoactive intestinal peptide in experimental prostate cancer : Antagonistic action of an analog of growth-hormone-releasing hormone (3)
Analysis of clinical studies with natural and synthetic luteinizing hormone-releasing hormone in man. (1974) (3)
Effect of synthetic hypothalamic gonadotropin-releasing hormone (FSH-LH-RH) in anovulatory sterility. (1974) (3)
Synthetic growth hormone-releasing hormone agonist ameliorates the myocardial pathophysiology characteristic of HFpEF. (2022) (3)
Effects of Administration of a LH-RH Inhibitory Analogue on Stages of the Rat Estrous Cycle 1 2 (1978) (3)
CRF-41 stimulates the release of beta-lipotrophin and beta-endorphin in normal human subjects. (1984) (3)
Comparative studies with beta-(Tyr9)melanotropin-(9-18) and amphetamine on open-field behavior and striatal dopamine uptake and release. (1984) (3)
On vasodepressor activity in the hypothalamus (1966) (3)
Stimulation of Release and Synthesis of Growth Hormone (GH) in Tissue Cultures of Anterior Pituitaries in Response to GH-Releasing Hormone (GH-RH) 1 (1970) (3)
Effects of cis-clomiphene on serum LH and prolactin levels and on the response to LH-RH in the ewe. (1972) (3)
Effect of Ala-2-D-Trp-8-D-Cys-14-somatostatin on the arginine induced release of insulin, GH and glucagon in normal men. (1984) (3)
Effects of growth hormone-releasing hormone receptor antagonist MIA-602 in mice with emotional disorders: a potential treatment for PTSD (2021) (3)
Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma (2018) (3)
Evaluation of the Biological Potency of New Agmatine Analogs of Growth Hormone-Releasing Hormone in the Bovine (1992) (3)
Effect of Intermittent Infusion of LH-Releasing Hormone on Serum LH and FSH Levels In Immature Male Rats 1 (1975) (3)
MON-478 Antinflammatory and Antioxidant Effects of MIA-690 and MR-409 in GHRHKO Mice Colon and Prefrontal Cortex (2019) (3)
Effect of D-Trp6-LH-RH on the pituitary-gonadal axis during the luteal phase in the baboon. (1979) (3)
Apoptosis in pancreatic cancers of hamsters (1994) (3)
Analogs of growth hormone-releasing hormone induce release of growth hormone in the bovine. (1988) (3)
Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in Primary Human Endometrial Carcinomas: Novel Therapeutic Approaches (2022) (3)
GHRH Receptor Expression in Malignant Mixed Müllerian Tumors: A Potentially Targetable Biopredictor (2016) (3)
Luteinizing hormone-releasing hormone antagonist Cetrorelix regulates the expression of Galphas and Galphai protein subunits and adenylate cyclase activity in rat ovary, breast and pituitary. (2004) (3)
TRIPTORELIN IN TREATMENT OF CERVICAL AND VAGINAL DYSPLASIA RELATED TO PAPILLOMAVIRUS (1988) (3)
Response to O-TRP-6-LHRH (decapeptyl) in dvarian cancer (1987) (3)
Effect of hypothalamic preparations on human omental adipose tissue in vitro. (1972) (3)
UN ANALOGUE DE LA GONADOLIBERINE DANS LE TRAITEMENT DES CARCINOMES PROSTATIQUES (1984) (3)
Effects of CRF-like heptapeptide on catecholamine disappearance and serotonin accumulation in different brain areas of rats (1982) (3)
Effects of in vivo treatment with an LHRH antagonist analog (D-PHE2-D-PHE6) in the immature male rat. (1978) (3)
Evaluation of luteinizing hormone-releasing hormone antagonistic activity in vitro. (1992) (3)
Further studies on the enzymatic and chemical inactivation of hypothalamic FSH-RH. (1971) (3)
On the presence in hog hypothalamus of 3-corticotropin releasing factor, alpha- and beta-melanocyte stimulating hormones, adrenocorticotropin, lysine-vasopressin and oxytocin. (1962) (3)
Effective treatment of triple-negative breast cancer with targeted cytotoxic somatostatin analogue AN-162 (AEZS-124). (2016) (3)
Effect of the isolated removal of the median eminence (ME) and pituitary stalk (PS) on the immunohistology and hormone release of the anterior pituitary gland grafted into the hypophysiotrophic area (HTA) and/or of the in situ pituitary gland. (1977) (2)
525 POSTER Targeting Doxorubicin to LHRH-receptor positive tumors by the cytotoxic hybrid ZEN-008 (AN-152) (2006) (2)
Biphasic fluctuation of pituitary responsiveness to LH-RH during the rat estrous cycle. Role of endogenous LH-RH and ovarian steroids in its modulation. (1980) (2)
Antagonists of Growth Hormone-Releasing Hormone Inhibit the Growth of Pituitary Adenoma Cells by Hampering Oncogenic Pathways and Promoting Apoptotic Signaling (2021) (2)
Effect of 6-dehydro-16-methylene-hydrocortisone and dexamethasone on the release of ACTH from rat pituitary glands in vitro. (1970) (2)
Potent agonists of growth hormone-releasing hormone. II. (1992) (2)
Leap of Faith : Does Serum Luteinizing Hormone Always Accurately Reflect Central Reproductive Neuroendocrine Activity ? (2015) (2)
Bombesin and epidermal growth factor potentiate the effect of cytotoxic LH-RH analog AN-152 in vitro. (2002) (2)
Analogs of Luteinizing Hormone-Releasing Hormone (lhrh) in Cancer (2006) (2)
Antagonist of growth hormone-releasing hormone MIA-690 attenuates the progression and inhibits growth of colorectal cancer in mice (2022) (2)
Disapearance and excretion of labeled alpha-MSH in man. (1978) (2)
Branched-chain analogs of luteinizing hormone-releasing hormone (1978) (2)
Treatment of Precocious Puberty with LHRH Agonists (1986) (2)
Direct growth inhibition of human endometrial cancer cells by the gonadotropin‐releasing hormone antagonist SB‐75: Role of apoptosis (1994) (2)
Phase I study of ZEN-008 (AN-152), a targeted cytotoxic LHRH analog, in female patients with cancers expressing LHRH receptors. (2006) (2)
Simultaneous localization of luteinizing hormone-releasing hormone (LH-RH) and somatostatin-containing nerve fibres in the brain of the rat. (1978) (2)
[The discovery of hypothalamic hormones and the development of antitumor analogs]. (2005) (2)
Melanocyte-stimulating hormone and the hypothalamic hormone which inhibits its release. (1974) (2)
LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) RECEPTORS IN BPH AS POTENTIAL MOLECULAR TARGETS FOR THERAPY WITH CETRORELIX (2008) (2)
Effect of thyrotropin (TSH)-releasing factor (TRF) on plasma TSH levels in nutria (Myocastor coypus). (1969) (2)
Induction of ovulation with synthetic gonadotrophin-releasing hormone in women with constant anovulation induced by contraceptive steroids. (1975) (2)
An In Vitro System for the Study of the Neural Control of ACTH Secretion (1958) (2)
Comparison of the effect of subcutaneous and intravenous injection of synthetic LH-releasing hormone (LH-RH) on serum LH and FSH levels in men. (1973) (2)
Agonist of growth hormone–releasing hormone enhances retinal ganglion cell protection induced by macrophages after optic nerve injury (2021) (2)
Absence of growth hormone-releasing factor in the posterior pituitary lobe of the rat. (1967) (2)
Unaltered plasma GH levels in acromegalics and normal men and women after administration of (Pyro)Glu-Ser-Gly-NH2, a proposed GH-releasing hormone. (1974) (2)
LHRH analogues and breast cancer. (1991) (2)
DIFFERENTIAL EFFECT OF D-TRP-6-LH-RH IN MICROCAPSULES (LRH-M) UPON LH AND LHα RELEASE DURING LONG TERM TREATMENT OF PRECOCIOUS PUBERTY (PP) (1986) (2)
Studies on corticotropin releasing factor: ion exchange chromotography of pituitary preparations. (1960) (2)
[35] Solid phase synthesis of luteinizing hormone-releasing hormone and its analogues (1975) (2)
Effect of catecholamines infused into a hypophysial portal vessel on serum prolactin levels in the rat (1974) (2)
Comparison of methionine-enkephalin and morphine in the stimulation of gastric secretion (1978) (2)
A phase I dose-escalation trial of AEZS-108 in taxane- and castration-resistant prostate cancer (CRPC). (2013) (2)
Activity of the GHRH Antagonist MIA602 and its Underlying Mechanisms of Action in sarcoidosis (2020) (2)
The Amino Acid Sequence of a Peptide with Growth (1971) (2)
Pharmacological characteristics of a synthetic releasing hormone LH-FSH-RH (Hoe 471). I. Release of luteinizing hormone. (1972) (2)
EXTRA PITUITARY EFFECTS OF THE GROWTH HORMONE-RELEASING HORMONE (2005) (2)
Expression of GHRH-R, a Potentially Targetable Biomarker, in Triple-negative Breast Cancer (2018) (2)
87 EFFECT OF CRF 1–41 AS COMPARED TO INSULIN HYPOGLYCEMIA (ITT) ON PLASMA CORTISOL AND ACTH IN SUBJECTS WITH INTACT OR DEFECTIVE HYPOTHALAMIC-PITUITARY FUNCTIONS (1985) (2)
D-Tryptophan-6-luteinizing hormone-releasing hormone in the treatment of normogonadotropic oligoasthenozoospermia. (1982) (2)
Plasminogen activator and nuclear androgen receptor in rat prostate tumors after treatment with D-Trp-6-LH-RH. (1984) (2)
Update on endocrine-related tumors. (2008) (2)
Physiological and Biochemical Studies on Some Highly Purified Hypothalamic Releasing Factors (1968) (2)
Comparison of the subcutaneous and intranasal administration of an LH-RH antagonist ([N-Ac-d-p-Cl-Phe1,2,d-Trp3,d-Arg6,d-Ala10]-LH-RH) in the rhesus monkey (1985) (2)
190 LONG TERM THERAPY OF PRECOCIOUS PUBERTY WITH THE SUPERACTIVE LH-RH ANALOGUE D-TRP-6-LH-RH (1985) (2)
Characterization of receptors for growth hormone-releasing hormone in human osteosarcomas and Ewing's sarcomas. (2006) (2)
A study on the mode of administration of thyrotropin releasing hormone (TRH) in mice. (1970) (2)
Dexniguldipine hydrochloride inhibits growth of human ht-29 colon-carcinoma cells and expression of protein-kinase-C-delta and protein-kinase-C-zeta. (1995) (2)
Changes in intra-ovarian pressure in woman following the administration of luteinizing hormone-releasing hormone LH-FSH). (1974) (2)
Photo-oxidation of thyrotropin releasing hormone (1971) (2)
Methods for estimating the biologic activity of the luteinizing hormone- and follicle stimulating hormone-releasing hormone. (1975) (2)
The use of peptide analogs for the treatment of gastrointestinal, pancreatic, liver and urinary bladder cancers (2010) (2)
Differential effect of various doses of mestranol on the release of luteinizing hormone and follicle-stimulating hormone in response to luteinizing hormone-releasing hormone. (1974) (2)
Effect of a somatostatin analogue on trophic hormone levels in acromegalic patients with elevated hGH after adenomectomy and treatment with bromocriptine. (2009) (2)
The role of central dopaminergic systems in the behavioral effects of H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH (1985) (2)
Treatment of male and female precocious puberty (PP) by monthly injections of a continuous release preparation of D-Trp-6-LH-RH (1984) (2)
Pituitary and Testicular Response to LH‐RH and to a Long‐Acting Analogue (D‐Leu‐6‐LH‐RH‐Ethylamide) (2009) (2)
Immunoreactive somatostatin levels in hypophyseal portal blood of rats anesthetized with urethane, pentobarbital or althesin (1978) (2)
Dose response inhibition of the circhoral pulsatile secretion of LH and FSH in rhesus monkeys by the administration of a potent inhibitory analogue of LH-RH ( [N-Ac-D-Trp1, 3, D-p-Cl-Phe2, D-Phe6, D-Ala10]-LH-RH). (1983) (2)
Impact of growth hormone-releasing hormone antagonist on decidual stromal cell growth and apoptosis in vitro (2021) (2)
Correlation between the Expression of Angiogenic Factors and Stem Cell Markers in Human Uveal Melanoma (2020) (1)
The actions of growth hormone release inhibiting hormone in man (1975) (1)
[Hypothalamic control of pituitary function with special reference to reproduction. Clinical and experimental studies]. (1972) (1)
STUDY ON MECHANISM OF ACTION OF 6-DEHYDRO-16-METHYLENE-HYDROCORTISONE (StC 407) IN RATS (1969) (1)
Growth hormone releasing hormone-receptor antagonist MIA-602 modulates lung inflammation, cellular signal transduction, and promotes apoptosis of mouse lung fibroblasts (2020) (1)
A Novel Therapeutic Effect of MIA-602 on an In Vitro Sarcoidosis Model (2020) (1)
Clinical Studies With d-Trp6-Luteinizing Hormone-Releasing Hormone in Anovulatory Women**Supported by a grant from Patronato de Investigaciones Endocrino Metabólicas, Fundación General Mediterránea, Madrid, Spain. (1978) (1)
A phase II trial of zoptarelin doxorubicin in castration- and taxane-resistant prostate cancer. (2017) (1)
Investigational strategies for detection and intervention in early-stage pancreatic cancer (1994) (1)
Expression of GHRH-R in primary and metastatic mammary carcinomas. (2014) (1)
Endogenous phosphorylation in Dunning prostate tumors of rats treated with LH-RH analogues. (1985) (1)
Role of nitric oxide in the antiproliferative signal mediated by the somatostatin receptor sst5 (1998) (1)
Contraceptive potential of analogs of LH-RH. (1984) (1)
Tc-99m labeled somatostatin analogue, RC-160: 1H-NMR and computer modeling conformational analysis (1994) (1)
Treatment with small doses of D-Trp6-LH-RH does not inhibit the gonadotrophine pituitary responsiveness in anorexia nervosa (1984) (1)
Inhibition of growth hormone and glucagon release by Phe-4-somatostatin in patients with acromegaly. (1984) (1)
Inhibition of growth of squamous cell prostate carcinoma in rats treated with D-TRP6-LHRH (1981) (1)
CONCENTRATION OF CORTICOTROPIN RELEASING FACTOR (CRF) IN ACID EXTRACTS OF SHEEP HYPOTHALAMUS BY GEL FILTRATION AND COUNTER CURRENT DISTRIBUTION. (1963) (1)
An LH-RH antagonist inhibits the behavioral effects of the agonist D-TRP-6-LH-RH in mice (1992) (1)
Re-evaluation of "frontal deafferentation" studies on the regulation of ACTH secretion in the light of CRF immunohistology. (1985) (1)
Antagonists of Bombesin and Gastrin-Releasing Peptide (2003) (1)
Successful induction of ovulation with synthetic luteinizing hormone-releasing hormone in anovulatoy infertility. (1973) (1)
A Novel Therapeutic Effect of MIA-602 Presented in an In Vivo Sarcoidosis Mouse Model (2020) (1)
A phase I trial of AEZS-108 in castration- and taxane-resistant prostate cancer. (2012) (1)
Effects of GnRH Agonists on Pituitary Gonadotropins: Dissociated Secretion of Subunits in Children with Precocious Puberty Treated with [D-Trp6]LHRH Microcapsules (1990) (1)
Investigational strategies for detection and intervention in early-stage pancreatic cancer (1994) (1)
Influence of the chronic administration of LH-RH agonist on the oral glucose tolerance test in patients with prostatic carcinoma. (1987) (1)
Publisher Correction: Antinflammatory, antioxidant, and behavioral effects induced by administration of growth hormone-releasing hormone analogs in mice (2020) (1)
Radioprotection by Antagonists of Growth Hormone Releasing Hormone during Whole Body Radiation is Dependent on the Radiation Dose (2009) (1)
CYCLIC ANALOGS OF LUTEINIZING HORMONE-RELEASING HORMONE WITH SIGNIFICANT BIOLOGICAL ACTIVITIES (1979) (1)
Response to LH-RH in men infused with theophylline. (1974) (1)
Abstract 91: Powerful inhibition of human renal cell carcinomas with antagonists of growth hormone-releasing hormone (GHRH): a preclinical study. (2013) (1)
Ovulation Induction: Ovarian Response to Human Gonadotropins and Synthetic Gonadotropin-Releasing Hormone (1975) (1)
Mechanisms of control of LH and FSH secretion. (1976) (1)
Endogenous phosphorylation in dunning prostate tumors of rats treated with LH‐RH analogues (1984) (1)
Clearance of lung metastases of breast carcinoma after treatment with triptorelin in postmenopausal woman (1995) (1)
Selective inhibitory effect of the analog D5-F-TrP8-D-Cys14 somatostatin on the arginine induced release of insulin, growth hormone and glucagon, in normal human beings. (1985) (1)
GHRH-receptor as a new targetable biomarker in breast cancer and its correlation with ER/PR/HER2 status. (2015) (1)
[Therapeutic effectiveness of the gonadotropin releasing hormone analogue D-Trp-6-LHRH in the treatment of precocious puberty]. (1988) (1)
Modified in vitro assay for melanocyte-stimulating hormone (1969) (1)
FSH-RELEASING ACTIVITY OF A SYNTHETIC DECAPEPTIDE (LH/FSH-RH) (1972) (1)
[Response to acute administration of pituitary inhibiting hormone, growth hormone and one of its analogues in acromegaly]. (1975) (1)
[Treatment with D-Trp-6-LHRH. Plasma levels and gonadotropic response]. (1984) (1)
Preclinical efficacy of growth hormone-releasing hormone antagonist MIA-602 for androgen-dependent and castration-resistant human prostate cancer. (2014) (1)
Agonists of LHRH (2003) (1)
Effect of novel growth hormone-releasing hormone antagonists on growth of experimental renal cell carcinomas. (2013) (1)
STIMULATION OF GROWTH HORMONE AND PROLACTIN RELEASE BY MORPHINE AND OPIATE-LIKE PEPTIDES (1978) (1)
[From the discovery of hypothalamic hormones to the development of analogues as anti-cancer agents]. (2005) (1)
Detection of growth hormone-releasing hormone in cytologic specimens of primary breast carcinoma. (2005) (1)
Thyrotropic Hormone Releasing Factor (TRF). Its Chemistry and Physiology (1966) (1)
Inhibition of testosterone production and pituitary LH-RH binding in rats by LH-RH antagonists (1980) (1)
The use of long-acting LH-RH analogs in the treatment of female infertility. (1976) (1)
Effects of H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH on the in vitro uptake and release of radiolabelled dopamine, noradrenaline and serotonin in rat brain hypothalamic slices (1984) (1)
EFFECT OF SIMPLE AMINO ACID REPLACEMENTS ON THE BIOLOGICAL ACTIVITY OF LUTEINIZING HORMONE-RELEASING HORMONE (1974) (1)
Isolation and structure of a hexapeptide from pig neurohypophysis. (1968) (1)
Expression of Luteinizing Hormone-Releasing Hormone (LHRH) and Type-I LHRH Receptor in Transitional Cell Carcinoma Type of Human Bladder Cancer (2021) (1)
Activation of Mitogen Activated Protein Kinases by a Splice Variant of Growth 5 Hormone Releasing Hormone Receptor 6 7 (2009) (1)
Orally Active Analogs of Luteinizing Hormone-Releasing Hormone (1976) (1)
Antagonists of Growth Hormone–Releasing Hormone (GHRH) in Cancer (2006) (1)
Comparison of effects of 6-dehydro-16-methylene-hydrocortisone (STC 407) and dexamethasone on the suppression of the hypothalamo-pituitary-adrenal system. (1970) (1)
Treatment of urinary bladder cancers by growth hormone-releasing hormone antagonists: A preclinical report. (2016) (1)
Analogue AN-238 Cancer and Its Metastases by Cytotoxic Somatostatin Inhibition of PC-3 Human Androgen-independent Prostate (1999) (1)
Effects of a superactive analogue of LH-RH on the hypothalamo-pituitary-testicular axis in male rats pretreated with estrogens. (1981) (1)
Erratum: Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance (Proceedings of the National Academy of Sciences of the United States of America (2014) 111, 7 (2686-2691) DOI: 10.1073/pnas.1400419111) (2014) (1)
hGH RESPONSE TO REPEATED GH-RH 1-44 ADMINISTRATION IN HYPOPITUITARY CHILDREN (1986) (1)
Growth hormone-releasing hormone (GHRH) promotes survival and proliferation of neural stem cells and reduces amyloid-β-induced toxicity (2020) (1)
Rat anterior pituitary perfusion: release of RIA GH by purified porcine GH RH (1973) (1)
[New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin]. (2004) (1)
A randomized, phase II trial of AEZS-108 in chemotherapy refractory triple-negative (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer. (2013) (1)
Selective coupling of methotrexate to peptide hormone carriers through a y-carboxamide linkage of its glutamic acid moiety : Benzotriazol-1-yloxytris ( dimethylamino ) phosphonium hexafluorophosphate activation in salt coupling ( drg targeting / cyttooic peptides / slte-seectve conJugation / chemoth (2005) (1)
Growth hormone-releasing hormone antagonistic analog MIA-690 stimulates food intake in mice (2021) (1)
Monitoring and treatment of minimal residual cancer of the prostate. (1989) (1)
Expression of Somatostatin Receptor Subtypes (SSTR-1–SSTR-5) in Pediatric Hematological and Oncological Disorders (2020) (1)
Hypothalamic peptide hormones and their analogues (1978) (1)
Synthetic Growth Hormone-Releasing Hormone Agonist as Novel Treatment for Heart Failure with Preserved Ejection Fraction (2020) (1)
Synthesis of D Phe2, Phe3, D Phe6 LH RH, a potent inhibitor of LH RH (1975) (1)
Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma (2022) (1)
Abstract 15998: Therapeutic Effectiveness Against Heart Failure With Preserved Ejection Fraction by the Activation of the Growth Hormone-releasing Hormone Receptor in a Murine Model (2020) (0)
Effects of danazol on the serum gonadotropin levels and the response to luteinizing hormone releasing hormone in ovariectomized rats treated or not with estradiol and progesterone (1977) (0)
INFLAMMATION‐INDUCED PROSTATIC ENLARGEMENT AND PROLIFERATION OF PROSTATE EPITHELIAL CELLS IS REDUCED BY GROWTH HORMONE‐RELEASING HORMONE (GHRH) ANTAGONISTS THROUGH THE INHIBITION OF EPITHELIAL‐TO‐MESENCHYMAL TRANSITION: MP17‐03 (2017) (0)
Isolation andstructure ofpro-somatostatin : A putative somatostatin precursor frompighypothalamus (amino acid sequence/pro-hormone) (1980) (0)
The effects of different receptor blockers on the H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH induced inhibition of extinction of active avoidance behaviour. (1988) (0)
CYTOPROTECTIVE EFFECT OF GROWTH HORMONE RELEASING HORMONE AGONIST IN CARDIAC STEM CELLS (2013) (0)
Effects of growth hormone-releasing hormone agonistic analog MR-409 on insulin-secreting cells under cyclopiazonic acid-induced endoplasmic reticulum stress (2021) (0)
Targeted therapy of gynecological tumors with cytotoxic peptide analogs (2006) (0)
Anti-luteinizing (LH)-releasing activity of several analogues of LH-releasing hormone. (1975) (0)
Octapeptides contenant de la lysine biologiquement active (1986) (0)
EXPRESSION OF LH-RH RECEPTORS AND mRNA FOR LH-RH RECEPTORS IN PATIENTS WITH LOCALIZED PROSTATE CANCER (1999) (0)
Growth hormone-releasing hormone agonist attenuates vascular calcification in diabetic db/db mice (2023) (0)
MP81-04 ALTERATIONS OF TUMOR MICROENVIRONMENT BY NITRIC OXIDE DONOR IMPEDES CASTRATION RESISTANT PROSTATE CANCER GROWTH (2019) (0)
Hypothalamic Releasing Factors: Distribution of Samples (1968) (0)
Abstract 16577: Cardioprotective Effect of Growth Hormone Releasing Hormone in Mouse Model of Heart Failure With Preserved Ejection Fraction (2016) (0)
Bombesin antagonists inhibit estrogen-independent breast the expression of the ErbB-2, and c-jun and c-fos oncogenE (2016) (0)
Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin (decreased cancer cell survival/change in hormonal environment) (2016) (0)
Effects of H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH on different behavioral tests of rats (1985) (0)
Agonistes de ghrh pour le traitement de troubles ischémiques (2013) (0)
Antitumor effects of growth hormone-releasing hormone (GHRH) antagonists in ACTH and GH-secreting pituitary adenoma cell lines (2019) (0)
GH-RH antagonists fluorinated (2010) (0)
45 EFFECT OF ATRIAL NATRIURETIC PEPTIDE ON THE HORMONE RELEASE IN SUPERFUSED RAT PITUITARY CELLS (1986) (0)
Effect of met-enkephalin and morphine on gastric secretion and blood flow. (1981) (0)
Contents, Vol. 13, 1973/1974 (1973) (0)
Investigation of the Combination of the Agonist D-Trp-6-LH-RH and the Antiandrogen Flutamide in the Treatment of Dunning R-3327H Prostate Cancer Model (1985) (0)
Efficacy of a Growth Hormone-Releasing Hormone Agonist in a Murine Model of Cardiometabolic Heart Failure with Preserved Ejection Fraction (2022) (0)
Immunohistochemical expression of receptors for luteinizing hormone-releasing hormone (LHRHR) in muscle-invasive Urothelial carcinoma of urinary bladder: a potential predictive marker for targeted cytotoxic LHRH hybrid analogs (2020) (0)
Combination of a novel growth hormone releasing hormone Antagonist JMR 132 and Tamoxifen enhances the inhibitory effects on growth of ZR 75 and T47D estrogen dependent human breast cancer cells in vitro and in vivo (2009) (0)
Somatostatin Receptor 2 Expression in Squamous Cell Carcinoma of the Conjunctiva. (2018) (0)
Effectiveness of Growth Hormone–Releasing Hormone Agonists (GHRH-A) in Chronic Kidney Disease-Induced Heart Failure with Preserved Ejection Fraction (2020) (0)
247 Treatment with luteinizing-hormone releasing-hormone analog in patients with prostatic carcinoma (1983) (0)
ISOLATION OF GRAM AMOUNTS OF ARGININE VASOPRESSIN, OXYTOCIN, AND ALPHA-MSH. (1964) (0)
Solid phase synthesis on luteinizing hormone-releasing hormone and its analogues. (1975) (0)
Growth Hormone Releasing Hormone Agonist Improves Cardiometabolic Parameters In A Murine Model Of Heart Failure With Preserved Ejection Fraction (2023) (0)
2539 A phase II trial of AEZS-108 in castration and taxane resistant prostate cancer (2015) (0)
New peptides, their preparation and containing the same drug (1976) (0)
Changes in the32P incorporation in rat mammary tumor after chronic administration of LH-RH analogs (1985) (0)
SYNTHESIS AND BIOLOGICAL ACTIVITY OF POSITION 1 ANALOGS OF LH-RH (1977) (0)
Abstract. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit growth of various human cancers including osteosarcomas and Ewing's sarcomas, xenografted into nude mice or cultured in vitro. The antiproliferative effect of GH-RH (2006) (0)
Luteinizing Hormone-Releasing Hormone and Its Agonistic, Antagonistic, and Targeted Cytotoxic Analogs in Prostate Cancer (2010) (0)
In vivo assay for melanocyte lightening substances (1966) (0)
Combination of antagonists of growth hormone-releasing hormone antagonist (GHRH) with rapamycin as a potential therapy in human breast cancers. (2010) (0)
Treatment of 7 V-Nitrosobis ( 2-oxopropyl ) amine-induced Pancreatic Cancer in Syrian Golden Hamsters with D-Trp-6-LH-RH and Somatostatin Analogue RC-160 Microcapsules 1 (2006) (0)
Growth hormone-releasing hormone (GHRH) antagonist induces apoptosis in retinoblastoma (2016) (0)
CHEMISTRY AND PHYSIOLOGY OF FOLLICLE-STIMULATING HORMONE-RELEASING FACTOR AND LUTEINIZING HORMONE-RELEASING FACTOR* (1968) (0)
Review Article: Latour's Prosaic Science (2016) (0)
Expression of LHRH receptors in prostate cancer cells prior to therapy, following castration, or following treatment with LHRH agonists. (2009) (0)
SYNTHESIS AND BIOLOGICAL ACTIVITY OF LH-RH ANALOGS MODIFIED AT THE CARBOXYL TERMINUS (1975) (0)
CELLULAR AND MOLECULAR BASES OF NEUROENDOCRINE PROCESSES (SYMP. INT. SOC. PSYCHONEUROENDOCRINOL.) (1976) (0)
7043 POSTER A Phase l/lI Trial of AN-152 in Castration- and Taxane-Resistant Prostate Cancer (2011) (0)
Hypothalamic releasing factors: distribution of samples. (1968) (0)
Physiological studies on the LH- and FSH- releasing hormone its analogues, and antisera. (1974) (0)
Subject Index Vol. 13, 1973/1974 (1973) (0)
Phase 1 trial of zoptarelin doxorubicin (Zop-Dox) in advanced unresectable or metastatic urothelial carcinoma (UC) patients who failed platinum-based chemotherapy. (2014) (0)
Release of immunoreactive somatostatin by tolbutamide from the rat pancreatic islets perifused in vitro (1978) (0)
Carcinoma the Proliferation of Experimental Non-Small Cell Lung Antagonists of Growth Hormone-Releasing Hormone Inhibit (2003) (0)
ENETS Newsletter Summer/Fall 2012 (2012) (0)
MP-02.04: Reduction in Prostate Size after Treatment with Cetrorelix in a Rat Model of Benign Prostatic Hyperplasia (BPH) (2009) (0)
Inhibition ofgrowth ofOV-1063 humanepithelial ovarian cancer xenografts innudemicebytreatment withluteinizing hormone-releasing (1994) (0)
P06 05 SP – OVARIAN PROTECTION IN MICE PRETREATED WITH LH-RH ANALOGS BEFORE IRRADIATION (1991) (0)
The role of the nucleus accumbens septi (NAS) in the behavioral action of β-(Tyr9)melanotropin-(9–18) (1985) (0)
Subject Index Vol. 6, 1970 (1970) (0)
Isolation and structure of pro-methionine-enkephalin: Potential enkephalin precursor from porcine hypothalamus (endorphins/pro-hormones) (0)
Thyrotrophin and prolactin response to beta-(pyrazolyl-1)-alanine-2-TRH in normal males. (1981) (0)
Biological activity of a synthetic decapeptide corresponding to the proposed growth hormone-releasing hormone (1972) (0)
Reply to Liu et al.: Hypothalamic control of islets (2011) (0)
[Synthetic hypothalamic gonadotropin-releasing hormone (LH-RH) and ovulation: a possibility of "programmed" ovulation to regulate fertility in women (author's transl)]. (1975) (0)
[Synthetic hypothalamic gonadotropin-releasing hormone -- LH-RH -- and ovulation: a possibility of programmed ovulation to control fertility in women.)] (1975) (0)
Effects of GHRH-R Antagonist MIA-602 or Agonist MR-409 on Human iAT2 Cells Exposed to Cytokines or LPS (2022) (0)
The role of the hypothalamus in reproduction (1974) (0)
THE EFFECTS OF A GROWTH HORMONE-RELEASING HORMONE ANTAGONIST AND A GASTRIN-RELEASING PEPTIDE ANTAGONIST ON INTIMAL HYPERPLASIA OF THE CAROTID ARTERY AFTER BALLOON INJURY IN A DIABETIC RAT MODEL (2013) (0)
ANTAGONSTC EFFECT OF PEPTIDC COMPOUNDS ON HORMONE-DEPENDENT DISEASES (2017) (0)
Letter: Analogues of growth-hormone release-inhibiting hormone. (1975) (0)
Alveolar Type 2 Cell Growth Hormone Releasing Hormone Receptor (GHRH-R) Modulates Inflammatory and Fibrotic Signaling (2023) (0)
Somatostatin Receptor-2 Expression in Sebaceous Carcinoma of the Ocular Adnexae (2017) (0)
Somatostatin Receptor-2 Expression in Sebaceous Carcinoma of the Ocular Adnexae (2017) (0)
Immunohistological investigations on the LH-RH synthesizing neuron system of the rat (1976) (0)
Hypophysectomized Rhesus Monkeys (Macaca mulatta) (1981) (0)
Subject Index Vol. 6, 1970 (1970) (0)
Traitement des pubertés précoces par administration périodique d'une forme à libération programmée de D-TRP-6-LH-RH (décapeptyl en microcapsules) (1985) (0)
[History of clinical studies on hypothalamic hormone analogs in Mexico]. (2006) (0)
[On the existence of 2 types of substances with hypophysiotropic activity: a-CRF and beta-CRF (corticotrophin-releasing factor)]. (1960) (0)
Accélération de la cicatrisation des plaies par l'hormone de libération de l'hormone de croissance et ses agonistes (2011) (0)
Synthesis and biological actions of prosomatostatin ( somatostatin / synthetic prohormone / insulin / glucagon / growth hormone ) (0)
Tumors Producing Hypothalamic Hormones (2003) (0)
Growth hormone-releasing hormone (GHRH) promotes survival and proliferation of neural stem cells and reduces amyloid-[beta]-induced toxicity (2022) (0)
Antagonists of growth hormone-releasing hormone potentiate radiation response in prostate cancer. (2010) (0)
Abstract 4769: Growth hormone-releasing hormone (GHRH) antagonist attenuates cell motility of human endometrial cancer by down-regulating Twist and N-Cadherin expression. (2013) (0)
Unaltered plasma prolactin levels in men after administration of synthetic LH-releasing factor. (1973) (0)
Selective inhibition of sleep related growth hormone release by Phe-4-somatostatin. (1984) (0)
Single Case of a Complete Response in a Metastatic Urothelial Carcinoma Patient Treated with Zoptarelin Doxorubicin (2014) (0)
Abstract 244: Cytoprotective Effect of Growth Hormone Releasing Hormone Agonist in Cardiac Stem Cells (2014) (0)
Experimental therapy of ES-2 human platinum resistant ovarian cancer with targeted cytotoxic somatostatin and LHRH analogues (2008) (0)
Monitoring and treatment of minimal residual cancer of the prostate. (1988) (0)
[Treatment of prostatic cancers by periodic administration of a delayed-release preparation of D-Trp(6)-LHRH]. (1986) (0)
The Growth Hormone Releasing Hormone Signaling Pathway Governs Cardiomyocyte differentiation in human iPS cells (2022) (0)
[Treatment of prostatic cancer with an LH-RH agonist: the D Trp6 LH-RH. Preliminary results in 30 cases]. (1984) (0)
387. Steroid induced changes in the release of LH and FSH after LH-RH administration in human beings (1974) (0)
α-Melanocyte Stimulating Hormone Has Anti-Inflammatory Properties in Granuloma Via Marco and p-CREB (2019) (0)
Combined hormonal therapy and chemotherapy for pancreatic cancer: Use of cytotoxic peptide analogs for targeted chemotherapy (1994) (0)
Inhibition of tumor growth of MDA-MB–231 human breast cancers by targeted cytotoxic analogue of somatostatin AN–162 (AEZS–124) (2008) (0)
Abstract 398: Growth Hormone Releasing Hormone Agonist (GHRH-A) Restores Cardiac Function in a Rodent Model of Heart FailureWith Preserved Ejection Fraction (HFpEF) (2017) (0)
[Induction of ovulation: Comparative study on the response of the ovary to the treatment with human gonadotropins, synthetic hypothalamic gonadotropin-releasing hormone (LH-RH) and nonhormonal agents (clomiphene, cyclophenyl, etc). Therapeutic studies on the treatment of anovulatory sterility]. (1973) (0)
Effects of an anti LH RH serum in gonadal function of hamsters (1975) (0)
Medical vs surgical orchiectomy in advanced prostatic cancer (1987) (0)
Abstract 214: Reduction of Scar Tissue after GHRH-A Treatment in a Swine Model of Sub-acute Ischemic Cardiomyopathy (2014) (0)
Agonistes de l'hormone de libération de l'hormone de croissance en tant qu'effecteurs de la survie et de la prolifération d'îlots pancréatiques (2011) (0)
Peptide Antagonist ( RC-3095 ) in Nude Mice by Treatment with Bombesin / Gastrin Releasing Inhibition of Growth of HT-29 Human Colon Cancer Xenografts (2006) (0)
Twenty-five Years of Endocrine Oncology with Analogs of Hypothalamic Peptides: An Overview (2003) (0)
1066 EFFECTIVE TREATMENT OF URINARY BLADDER CANCERS BY TARGETED CYTOTOXIC LHRH ANALOG AEZS-108 (AN-152) A PRECLINICAL REPORT (2012) (0)
Prostatic carcinoma treatment with a delayed-release microcapsules preparation of D-TRP-6-LH-RH (1986) (0)
Alterations in receptor-mediated kinases and phosphatases during carcinogenesis (1995) (0)
Delayed release of gonadotropins by LH-RH in rats pretreated with antiserum against LH-RH (1977) (0)
Classification of patients with GH deficiency (GHD) according to the response to GH-RH (1984) (0)
Isolation , structure , biological characterization , and synthesis of f 3-[ Tyr 9 ] melanotropin-( 9-18 ) decapeptide from pig hypothalami ( aand P-melanottopin / {-lipotropin / corticotropin precursor ) (0)
0141 Combination of antagonists of growth hormone-releasing hormone with docetaxel as potential therapy in breast cancer in a preclinical study (2009) (0)
PROC.V INT.CONGR.ENDOCRINOLOGY. VOL.I (1977) (0)
[Anthology of the first clinical studies with hypothalamic hormones: a story of successful international cooperation]. (2002) (0)
Oxygen-independent, hormonal control of HIF-1α regulates the developmental and regenerative growth of cardiomyocytes (2023) (0)
[An analog of gonadoliberin in the treatment of prostatic carcinoma]. (1984) (0)
Radiation inactivation of purified lysine vasopressin (1966) (0)
Growth hormone releasing hormone receptor (GHRH-R) antagonist MIA-602 modulates fibrosis and gene expression in lungs of bleomycin-treated mice (2019) (0)
324 TARGETED CYTOTOXIC ANALOG OF SOMATOSTATIN AN-162 [AEZS-124] INHIBITS PROLIFERATION OF PC-3 AND DU-145 HUMAN ANDROGEN-INDEPENDENT PROSTATE CANCERS IN VITRO AND IN VIVO (2013) (0)
Differential effect of d tryptophan 6 lhrh in microcapsules upon luteinizing hormone and luteinizing hormone alpha release during long term treatment of precocious puberty (1986) (0)
Contents, Vol. 6, 1970 (1970) (0)
Peptidergic appetite regulation. (1982) (0)
Contents, Vol. 6, 1970 (1970) (0)
The Somatostatin receptor subtypes SSTR2 and SSTR5 mediate the inhibition of cell proliferation (1995) (0)
Subject Index Vol. 8, 1971 (1971) (0)
LHRH antagonists, their preparation and pharmaceutical preparations relevant. (1988) (0)
(inhibitors of GH release/structure-activity relationships/cancer (2016) (0)
Purification and characterization of peptides with corticotropin-releasing factor activity from porcine hypothalami ( polypeptide structure / structural homology / displacement of peptides ) MIKLOS PATTHY (2003) (0)
GHRH/IGF-1 pathway in retinal progenitor cell differentiation (2017) (0)
Analogs of Peptide Hormones (2003) (0)
LHRH antagonists, their preparation and corresponding pharmaceutical preparations. (1988) (0)
New LHRH analogs with high antagonistic and antitumor activity (1993) (0)
Corticotropin-releasing factor ( CRF )-like immunoreactivity in the vertebrate endocrine pancreas ( immunocytochemistry / hormones / islets of Langerhans / evolution ) (0)
391. Influence of estradiol benzoate on the pituitary responsiveness to LH-RH at different stages of the estrous cycle in rats (1974) (0)
Growth hormone-releasing hormone (GHRH) antagonists, MIA-602 and MIA-690, inhibit survival and proliferation of human pleural mesothelioma cells (2017) (0)
Legends in urology. (2013) (0)
Effect of cycloheximide on the LH release induced by a superactive analog of LH-RH. (1980) (0)
Symposium on Biochemical and Clinical Aspects of Steroid Enzymology (1971) (0)
PHYSIOLOGICAL, VETERINARY, AND CLINICAL EFFECTS OF HYPOTHALAMIC RELEASING HORMONES (RH), ESPECIALLY LH‐RH (1974) (0)
Abstracts of the 6th Annual ENETS Conference, Granada, Spain, March 5–7, 2009 (2009) (0)
Quantitative aspects of percolation for the extraction of oxytocin and vasopressin. (1962) (0)
Subject Index Vol. 24, 1977 (1977) (0)
New Avenue in Islet Transplantation by Macroencapsulation and Islet Pre-Treatment with Growth Hormone Releasing Hormone Agonist: 1585 (2012) (0)
787 GROWTH HORMONE-RELEASING HORMONE ANTAGONIST INHIBITS GROWTH OF PC-3 HUMAN PROSTATE CANCER BY INACTIVATION OF ERK AND AKT (2012) (0)
SYNTHESIS AND BIOLOGICAL PROPERTIES OF THE 2-L-β-(PYRAZOLYL-1)ALANINE ANALOGS OF LUTEINIZING HORMONE-RELEASING HORMONE AND THYROTROPIN-RELEASING HORMONE (1976) (0)
A phase I trial of AEZS-108 (AN-152) in castration- and taxane-resistant prostate cancer. (2012) (0)
Oncostatic Effect of Analogs of LHRH on Breast Cancer (2008) (0)
Octapeptide somastatin analogs, processes for their preparation, and a pharmaceutical composition (1986) (0)
Analogs of Luteinizing Hormone-Releasing Hormone in the Treatment of Endometriosis (2015) (0)
Targeted Chemotherapy: New Approaches to Treatment of Various Cancers Based on Cytotoxic Analogs of Luteinizing Hormone-Releasing Hormone (LH-RH), Somatostatin and Bombesin (2016) (0)
105. The Study on the Clinical Use of Hypothalamic Hormones for the Contraception (1978) (0)
Analogues of luteinizing hormone-releasing hormone containing (2016) (0)
Hypothalamic LH and FSH releasing hormone; physiological and clinical studies. (1973) (0)
Proceedings of the Society for Experimental PSEBM (2008) (0)
Contents, Vol. 2, 1967 (1967) (0)
Abstract 56: Growth Hormone Releasing Hormone Improves Sarcomere Relaxation and Calcium Decline in Cardiomyocyte From a Mouse Model of Heart Failure With Preserved Ejection Fraction (2016) (0)
Re: editorial comment on LHRH antagonist cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia (Prostate 2011; 71: 736-747). (2013) (0)
[Effects of cerebral, hypothalamic and hypophyseal peptides on the central nervous system]. (1981) (0)
Expression Levels of GHRH-Receptor, pAkt and Hsp90 Predict 10-Year Overall Survival in Patients with Locally Advanced Rectal Cancer (2022) (0)
D 20453 - A potent antagonist of LB-RB in the treatment of DNBA induced mammary carcinoma (1990) (0)
Experimental therapy of PC-3 and DU-145 human androgen-independent prostate cancers with targeted cytotoxic analog of somatostatin AN-162. (2013) (0)
SYNTHESIS AND BIOLOGICAL PROPERTIES OF (2-L-BETA-(PYRAZOLYL-3)ALANINE)-LUTEINIZING HORMONE-RELEASING HORMONE (1974) (0)
Gene expression profile of LNCaP human prostate cancer cells after treatment with an antagonist of growth hormone-releasing hormone (2012) (0)
Histological Findings in the Rat Prostate Cancer Model During Treatment With a Luteinizing Hormone-Releasing Hormone Agonist and Novantrone (1988) (0)
Biphasic fluctuation of pituitary responsiveness during the estrous cycle in rats (1977) (0)
Use of LH-RH analogs for the treatment of hormone sensitive tumors, combination therapy, and direct effects (1986) (0)
Somatostatin receptor subtyl human pancreatic cancer cell ligand-induced apoptosis (2016) (0)
Abstract 1346: Magnetoelectric particles cross blood brain barrier to deliver anti-tumor peptide to glioblastoma cells with on-demand release (2016) (0)
Tumorigenic transformation of human prostatic epithelial cell line RWPE‐1 by growth hormone‐releasing hormone (GHRH) (2022) (0)
Dexniguldipine hydrochloride inhibits growth of human pancreatic adenocarcinoma cells and expression of protein kinase C isoforms alpha and zeta. (1996) (0)
1600 COMBINATION OF BOMBESIN/GASTRIN-RELEASING PEPTIDE ANTAGONIST WITH GROWTH-HORMONE-RELEASING HORMONE ANTAGONIST AUGMENTS SHRINKAGE OF BENIGN PROSTATIC HYPERPLASIA IN RATS (2013) (0)
Novel therapeutic strategies for the treatment of pheochromocytoma (2013) (0)
Abstract 5317: A novel approach to the treatment of ATRA/ATO resistant acute promyelocytic leukemia (2022) (0)
Phosphor-Einnahme, reaktionslose (1931) (0)
Hypothalamic Releasing Hormones (2020) (0)
SAT-603 Growth Hormone-Releasing Hormone (GHRH) Antagonists Stimulate Feeding in Mice (2020) (0)
Up-regulation Of Growth Hormone Releasing Hormone (GHRH) Receptors In The Ischemic Retina (2013) (0)
Subject Index Vol. 8, 1971 (1971) (0)
Tumor growth inhibition of MDA-MB–231 estrogen independent human breast cancer by treatment with antagonist of LHRH Cetrorelix® (2008) (0)
MIA602 Downregulates Bleomycin-Induced Fibrosis Mediated by Growth Hormone-Releasing Hormone Receptor Activation (2020) (0)
Long Term Experience with a Superactive GnRH Analog in the Treatment of Precocious Puberty (1990) (0)
Decrease in prolactin receptor affinity in the rat mammary tumor model after treatment with analogs of somatostatin and LH-RH. (1988) (0)
Effect of the infusion of p-Glu-His-Ala-OH, analog of the anorexigenic peptide, on the insulin response induced by intravenous glucose. Preliminary results with obese subjects. (1992) (0)
Effects of melanocyte stimulating hormone on a restricted passive avoidance response (1973) (0)
Luteinizing hormone-releasing hormone in the treatment of anovultory infertility. (1975) (0)
Synthesis heterocyclic compounds containing five or six rings (1996) (0)
Antagonists of bombesin/gastrin-releasing Peptide inhibit growth of jar human choriocarcinoma cells and production of cyclic-amp in-vitro. (1995) (0)
Fertility hormone research [9] (1971) (0)
A phase I trial of AEZS-108 (AN-152) in castration- and taxane-resistant prostate cancer. (2012) (0)
Contents, Vol. 24, 1977 (1977) (0)
Isolation and structure of pro-somatostatin : A putative somatostatin precursor from pig hypothalamus ( amino acid sequence / prohormone ) (0)
Agonists and Antagonists of Luteinizing Hormone-releasing Hormone (LHRH) in the Treatment of Endometriosis (2010) (0)
Abstract 723: Agonist of Growth Hormone Releasing Hormone Enhances Angiogenic Therapy by Mesenchymal Stem Cells (2015) (0)
GROWTH HORMONE‐RELEASING HORMONE (GHRH) ANTAGONISTS INHIBIT PROSTATIC ENLARGEMENT AND INFLAMMATION IN ?‐CARRAGEENAN‐INDUCED EXPERIMENTAL PROSTATITIS: MP45‐05 (2018) (0)
330 Preclinical development of BIS-1602, first in class growth hormone releasing hormone antagonist (2014) (0)
Foundations of the clinical use of LHRH: early studies with the porcine hypothalamic hormone. (1980) (0)
Thyroid stimulating and pigmentary effects of synthetic peptides related to alpha-MSH and ACTH. (1967) (0)
Re: Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist (2013) (0)
Antinflammatory, antioxidant, and behavioral effects induced by administration of growth hormone-releasing hormone analogs in mice (2020) (0)
Combination of a Novel Growth Hormone Releasing Hormone Antagonist JMR 132 and Tamoxifen Enhances the Inhibitory Effects on Growth of ZR 75 and T47D Estrogen Dependent Human Breast Cancer Cells In Vitro and In Vivo. (2009) (0)
Inhibition of growth of MCF-7 MIII human breast carcinoma treatment with agonists or antagonists of LH-RH in nude mice by (0)
Contents, Vol. 8, 1971 (1971) (0)
Correlation between leuteinizing hormone responses to luteinizing hormone-releasing hormone (LH-RH) and to D-leu-6-LH-RH-ethylamide in patients with hypothalamo-pituitary disease. (1976) (0)
Abstract 12236: Targeting Growth Hormone Releasing Hormone Receptor as a New Therapeutic Approach to Improve Cardiac Repair After Myocardial Injury (2013) (0)
Contents, Vol. 8, 1971 (1971) (0)
MP44-11 GROWTH HORMONE-RELEASING HORMONE (GHRH) ANTAGONISTS REDUCE INFLAMMATION- AND TRANSFORMING GROWTH FACTOR (TGF)-?2-INDUCED PROLIFERATION OF HUMAN BPH-1 PROSTATE EPITHELIAL CELLS GROWN IN 3D CULTURE (2016) (0)
Prostate carcinoma tumor size in r. administration of antagonists of lu hormone-releasing hormone (prostate adenocarcinoma/inhibitory analogues of luteinizing hormor (2016) (0)
Abstract 19957: Chronic Infusion of Growth Hormone Releasing Hormone Prevents Heart Failure With Preserved Ejection Fraction Phenotype Development in Murine Cardiomyocytes by Reducing Myofilament Sensitivity to Calcium (2017) (0)
The effect of beta-(Tyr9)melanotropin-(9-18) on the active avoidance and open-field behavior on rats pretreated with atropine or propranolol. (1984) (0)
Inhibition of implantation by the administration of anti-LHRH immunogamma globulin in rats (1977) (0)
[Effect of natural exogenous estrogens on the response to LH-RH (author's transl)]. (1976) (0)
LHRH antagonists, their preparation and medicines containing them (1988) (0)
Clinical Cancer esearch cer Therapy : Clinical ression of Receptors for Luteinizing Hormone-Releasing mone ( LH-RH ) in Prostate Cancers following Therapy R LH-RH Agonists (2010) (0)
STIMULATION OF LH RELEASE IN MEN AND WOMEN BY LH-RELEASING HORMONE PURIFIED FROM PORCINE HYPOTHALAMI (1970) (0)
Treatment of central precocious puberty with superactive lhrh analogues (1988) (0)
New Antagonists of Growth Hormone Releasing Hormone (GHRH-A) Given after Radiation for Prostate Cancer Enhance Tumor Response Through Gene Regulation (2010) (0)
Growth Hormone Releasing Hormone (GHRH) Agonist Improves Cardiac Performance in the Chronic Model of Myocardial Infarction (MI) in Rats (2010) (0)
Growth hormone-releasing hormone (GHRH) antagonists increase the sensitivity to radiotherapy in lung cancer cells (2020) (0)
Hormone-ReleasingHormone andAntagonists of Luteinizing Hormone-ReleasingHormone in Shrinking Experimental Benign ProstaticHyperplasia (2013) (0)
Abstract 18122: Reduction of Scar Tissue after GHRH-Agonist Treatment in a Swine Model of Sub-acute Ischemic Cardiomyopathy (2014) (0)
Effective tumor growth inhibition of MX1 and MDA-MB-231 estrogen receptor negative human breast cancer xenografts by treatment with LHRH antagonist cetrorelix. (2009) (0)
D-Trp6-LHRH-induced delay in vaginal opening correlated with changes in ACTH, prolactin and corticosterone levels (1980) (0)
Effect of Somatostatin on TSH levels in non-toxic sporadic goiter. (1990) (0)
Octapeptides biologiquement actifs contenant de la lysine (1986) (0)
Effect of immunological deprivation of endogenous LHRH on the course of pregnancy in rats (1978) (0)
Levels of Luteinizing Hormone (LH), Follicle-Stimulating Hormone, and 17β-Estradiol in Response to D-Trp6-LH-Releasing Hormone During Different Phases of the Menstrual Cycle in Normal Women**Supported by a grant from Patronato de Investigaciones Endocrino Metabolicas, Fundacion General Mediterranea, (1978) (0)
Antagonistes de LHRH, leur production et compositions pharmaceutiques s'y rapportant (1988) (0)
Hormone-Releasing Hormone Analog Beef Cows Injected with Microencapsulated Luteinizing Luteinizing Hormone Concentrations in Serum of Postpartum (2012) (0)
ANALOGS OF LUTEINIZING HORMONE-RELEASING HORMONE CONTAINING DERIVATIVES OF PHENYLALANINE IN PLACE OF TYROSINE (1973) (0)
Analogs of LH-RH in contraception and cancer (1984) (0)
Expression of SSTR2 somatostatin receptor subtype inhibted pancreatic tumor cell growth (1995) (0)
Blockade of ovulation in rats by an inhibitory analogue of LH-RH injected at different stages of estrous cycle. (Abstract only) (1976) (0)
Abstract 3831: Growth-Hormone-Releasing-Hormone (GHRH) Agonist as a Potential Cardioprotective Agent in Rats With Post-Myocardial Infarction (MI) (2009) (0)
ression of Receptors for Luteinizing Hormone-Releasing mone (LH-RH) in Prostate Cancers following Therapy (2010) (0)
Abstract 14807: Activation of the Growth Hormone-Releasing Hormone Receptor Prevents the Development of Heart Failure With Preserved Ejection Fraction in CD1 Mice (2019) (0)
Luteinizing hormone-releasing hormone (LH-RH) content in the hypothalamus of 65-day-old and 10-month-old male rats. (1972) (0)
Abstract 13849: Growth Hormone Releasing Hormone (GHRH) Receptor Dependency for Cardioprotective Repair (2011) (0)
[Prolonged treatment with LH-RH of 6 men with oligoasthenozoospermia and normogonadotropic idiopathic azoospermia]. (1982) (0)
Hormone-releasing Hormone in Man (1981) (0)
Abstract 19258: Cytoprotective Effect of Growth Hormone Releasing Hormone Agonists in Cardiac Stem Cells (2014) (0)
Growth Hormone Releasing Hormone Agonist Protects From Pneumolysin-Induced Pulmonary Permeability (2012) (0)
Proceedings: Effect of growth hormone release inhibiting hormone on the release of growth hormone and other pituitary hormones in man. (1974) (0)
A large dimension vertical apparatus for zone electrophoresis. (1960) (0)
Differentiation of somatostatin receptors involved in inhibition of gastric acid and growth hormone secretion with halogenated Trp8 analogues [proceedings]. (1978) (0)
Les antagonistes analogues du LH-RH en utilisation contraceptive chez la femme (1984) (0)
Abstract 2125: AN-162, a targeted cytotoxic analog of somatostatin, suppresses growth of human hormone refractory prostate cancers in vitro and in vivo. (2013) (0)
Process for the preparation of therapeutically useful nonapeptidibombesiiniantagonistien (1993) (0)
Plasma gonadotropin response to D-Ala6-LH-RH propylamide. (1978) (0)
Binding characteristics of cytotoxic analog of luteinizing-hormone releasing hormone (LH-RH) in membrane from human and MXT mammary cancer (1993) (0)
Influence of methionine-enkephalin and morphine on the myoelectrical activity of the small bowel (1978) (0)
Involvement of the unfolded protein response in the protective effects of growth hormone releasing hormone antagonists in the lungs (2020) (0)
Long-term response in a patient with urothelial cancer (UC) treated with AEZS-108. (2013) (0)
[(8-Homoargine) (luteinizing hormone releasing hormone) (author's transl)]. (1974) (0)
Cancer Therapy : Clinical Phase I , Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration-and Taxane-Resistant Prostate Cancer (2014) (0)
Synthesis and biological activities of analogs of hGH-RH with C-terminal agmatine (1991) (0)
Process for the preparation of novel therapeutically useful peptides (1988) (0)
Treatment of Various Tumors with Peptide Analogs (2003) (0)
Anti-inflammatory effects of α-MSH through p-CREB expression in sarcoidosis like granuloma model (2020) (0)
Assays of Hypothalamic Releasing and Inhibiting Hormones (1975) (0)
effects of growth hormone - releasing hormone antagonist JMR-132 (2008) (0)
The effect of analogues of hypothalamic hormones on the growth of the Swarm chondrosarcoma (1982) (0)
Antagonist of growth hormone-releasing hormone (GHRH) potentiates the antitumor effect of chemotherapy in human malignant pleural mesothelioma (2022) (0)
Subject Index Vol. 56, 1992 (1992) (0)
Advances in Brief Stimulation by Bombesin and Inhibition by Bombesin / Gastrin-releasing Peptide Antagonist RC-3095 of Growth of Human Breast Cancer Cell Lines 1 (2006) (0)
Preclinical Development Luteinizing Hormone-Releasing Hormone ( LHRH )-I Antagonist Cetrorelix Inhibits Myeloma Cell Growth In vitro and In vivo (2011) (0)
LH-RH analogs with cytotoxic moieties (1992) (0)
Evaluation of in vivo [corrected] biological activity of new agmatine analogs of growth hormone-releasing hormone (GH-RH) (1990) (0)
Somatostatin : A potent , selective inhibitor of growth hormone release ( peptides / pituitary / bioassay / receptors / somatotropin ) (2003) (0)
Experimental comparative study of adjuvant and neoadjuvant chemotherapy, or hormonotherapy or immunotherapy applied to a hormone receptor carrying murine mammary tumor (1988) (0)
Agonist of growth hormone-releasing hormone improves the disease features of spinal muscular atrophy mice. (2023) (0)
Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125 (2014) (0)
Studies using multichannel perifusion system: GH-releasing activity of neuropeptides and hypothalamic extracts (1981) (0)

This paper list is powered by the following services:

Other Resources About Andrew Schally

en.wikipedia.org

What Schools Are Affiliated With Andrew Schally?

Andrew Schally is affiliated with the following schools:

Image Attributions

Image Source for Andrew Schally